Definitive Healthcare (DH) 10-Q 2 Nov 23 2023 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2023	Oct. 31, 2023
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Entity Registrant Name	Definitive Healthcare Corp.
Entity Central Index Key	0001861795
Entity Tax Identification Number	86-3988281
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity File Number	001-40815
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	492 Old Connecticut Path
Entity Address, Address Line Two	Suite 401
Entity Address, City or Town	Framingham
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01701
City Area Code	508
Local Phone Number	720-4224
Trading Symbol	DH
Title of 12(b) Security	Class A Common Stock, $0.001 par value
Security Exchange Name	NASDAQ
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock Shares Outstanding		116,328,089

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 77,460	$ 146,934
Short-term investments	229,565	184,939
Accounts receivable, net	41,308	58,799
Prepaid expenses and other current assets	14,667	12,686
Current portion of deferred contract costs	12,396	10,387
Total current assets	375,396	413,745
Property and equipment, net	4,628	4,464
Operating lease right-of-use assets, net	9,951	9,681
Other assets	3,414	4,683
Deferred contract costs, net of current portion	16,132	14,596
Intangible assets, net	336,027	350,722
Goodwill	1,073,986	1,324,733
Total assets	1,819,534	2,122,624
Current liabilities:
Accounts payable	5,567	3,948
Accrued expenses and other current liabilities	35,986	26,855
Current portion of deferred revenue	89,713	99,692
Current portion of term loan	13,750	8,594
Current portion of operating lease liabilities	2,126	1,521
Total current liabilities	147,142	140,610
Long term liabilities:
Deferred revenue, net of current portion	68	236
Term loan, net of current portion	245,866	255,765
Operating lease liabilities, net of current portion	9,873	9,969
Tax receivable agreements liability, net of current portion	138,736	155,111
Deferred tax liabilities	65,461	75,737
Other long-term liabilities	8,938	3,251
Total liabilities	616,084	640,679
Equity:
Additional paid-in capital	1,077,332	970,207
Accumulated other comprehensive income	3,051	3,668
Accumulated deficit	(217,217)	(25,062)
Noncontrolling interests	340,168	533,027
Total equity	1,203,450	1,481,945
Total liabilities and equity	1,819,534	2,122,624
Common Class A
Equity:
Common stock, value	116	105
Common Class B
Equity:
Common stock, value	$ 0	$ 0

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Common Class A
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	600,000,000	600,000,000
Common stock, shares issued	116,281,962	105,138,273
Common stock, shares outstanding	116,281,962	105,138,273
Common Class B
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	65,000,000	65,000,000
Common stock, shares issued	39,781,946	50,433,101
Common stock, shares outstanding	39,129,867	48,923,952

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended		12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Income Statement [Abstract]
Revenue	$ 65,325			$ 57,382			$ 185,483	$ 162,054
Cost of revenue:
Cost of revenue exclusive of amortization	8,663			6,569			25,293	18,717
Amortization	3,232			3,155			9,676	14,113
Gross profit	53,430			47,658			150,514	129,224
Operating expenses:
Sales and marketing	22,804			21,184			70,929	66,062
Product development	10,759			9,205			30,872	24,761
General and administrative	14,545			14,349			42,294	35,440
Depreciation and amortization	9,795			10,037			29,073	30,105
Transaction, integration and restructuring expenses	3,505			2,945			9,666	6,362
Goodwill impairment	287,400			0			287,400	0	$ 0
Total operating expenses	348,808			57,720			470,234	162,730
Loss from operations	(295,378)			(10,062)			(319,720)	(33,506)
Other income (expense), net:
Interest income	3,464			608			9,870	858
Interest expense	(3,897)			(3,074)			(11,304)	(7,788)
Other income, net	29,589			5,628			25,161	9,716
Total other income, net	29,156			3,162			23,727	2,786
Net loss before income taxes	(266,222)			(6,900)			(295,993)	(30,720)
Benefit from income taxes	17,534			15			19,728	654
Net loss	(248,688)	$ (11,605)	$ (15,972)	(6,885)	$ (10,142)	$ (13,039)	(276,265)	(30,066)
Less: Net loss attributable to noncontrolling interests	(77,162)			(3,865)			(84,110)	(12,979)
Net loss attributable to Definitive Healthcare Corp.	$ (171,526)			$ (3,020)			$ (192,155)	$ (17,087)
Net loss per share of Class A common stock:
Basic	$ (1.5)			$ (0.03)			$ (1.72)	$ (0.17)
Diluted	$ (1.5)			$ (0.03)			$ (1.72)	$ (0.17)
Weighted average Class A Common Stock outstanding:
Basic	114,527,514			102,904,565			111,533,166	99,776,742
Diluted	114,527,514			102,904,565			111,533,166	99,776,742

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Statement of Comprehensive Income [Abstract]
Net loss	$ (248,688)	$ (6,885)	$ (276,265)	$ (30,066)
Other comprehensive loss:
Foreign currency translation adjustments	(30)	(207)	(134)	(417)
Unrealized gain (loss) on available-for-sale securities	205	46	(59)	(406)
Unrealized (loss) gain on interest rate hedging instruments	(442)	3,333	(686)	6,673
Comprehensive loss	(248,955)	(3,713)	(277,144)	(24,216)
Less: Comprehensive loss attributable to noncontrolling interests	(77,228)	(2,931)	(84,372)	(10,978)
Comprehensive loss attributable to Definitive Healthcare Corp.	$ (171,727)	$ (782)	$ (192,772)	$ (13,238)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN TOTAL EQUITY (Unaudited) - USD ($) $ in Thousands	Total	Class A Units	Class B Units	Additional Paid In Capital	Accumulated Deficit	Accumulated Other Comprehensive Income	Noncontrolling Interest
Beginning Balance at Dec. 31, 2021	$ 1,499,836	$ 97		$ 888,992	$ (17,840)	$ 62	$ 628,525
Beginning Balance (in shares) at Dec. 31, 2021		97,030,095	58,244,627
Net loss	(13,039)
Net loss					(8,581)		(4,458)
Other comprehensive Income	1,343					856	487
Vested incentive units				(696)			696
Effect of LLC unit exchanges	(893)	$ 1		5,071			(5,965)
Effect of LLC unit exchanges, shares		544,302	(544,302)
Equity-based compensation	6,872			4,377			2,495
Distributions to noncontrolling interests	(258)						(258)
Forfeited unvested incentive units			(33,549)
Ending Balance at Mar. 31, 2022	1,493,861	$ 98		897,744	(26,421)	918	621,522
Ending Balance (in shares) at Mar. 31, 2022		97,574,397	57,666,776
Beginning Balance at Dec. 31, 2021	1,499,836	$ 97		888,992	(17,840)	62	628,525
Beginning Balance (in shares) at Dec. 31, 2021		97,030,095	58,244,627
Net loss	(30,066)
Net loss	(17,087)
Ending Balance at Sep. 30, 2022	1,473,093	$ 105		961,001	(34,927)	3,911	543,003
Ending Balance (in shares) at Sep. 30, 2022		104,961,965	50,566,898
Beginning Balance at Mar. 31, 2022	1,493,861	$ 98		897,744	(26,421)	918	621,522
Beginning Balance (in shares) at Mar. 31, 2022		97,574,397	57,666,776
Net loss	(10,142)
Net loss					(5,486)		(4,656)
Other comprehensive Income	1,335					755	580
Vested incentive units				(358)			358
Effect of LLC unit exchanges	(4,592)	$ 2		24,764			(29,358)
Effect of LLC unit exchanges, shares		2,898,589	(2,898,589)
Equity-based compensation	9,005			5,852			3,153
Distributions to noncontrolling interests	(5,029)						(5,029)
Forfeited unvested incentive units			(22,807)
Issuance of Class A Common Stock upon vesting of RSUs, shares		11,729
Issuance of Class A Common Stock upon vesting of RSUs				45			(45)
Ending Balance at Jun. 30, 2022	1,484,438	$ 100		928,047	(31,907)	1,673	586,525
Ending Balance (in shares) at Jun. 30, 2022		100,484,715	54,745,380
Net loss	(6,885)
Net loss	(3,020)				(3,020)		(3,865)
Other comprehensive Income	3,172				2,238		934
Vested incentive units				(5,728)			5,728
Effect of LLC unit exchanges	(12,368)	$ 5		34,207			(46,580)
Effect of LLC unit exchanges, shares		4,172,933	(4,172,933)
Equity-based compensation	9,133			6,141			2,992
Distributions to noncontrolling interests	(1,652)						(1,652)
Forfeited unvested incentive units			(5,549)
Issuance of Class A Common Stock upon vesting of RSUs, shares		440,317
Issuance of Class A Common Stock upon vesting of RSUs				1,079			(1,079)
Shares withheld related to net share settlement (in shares)		(136,000)
Shares withheld related to net share settlement	(2,745)			(2,745)
Ending Balance at Sep. 30, 2022	1,473,093	$ 105		961,001	(34,927)	3,911	543,003
Ending Balance (in shares) at Sep. 30, 2022		104,961,965	50,566,898
Beginning Balance at Dec. 31, 2022	1,481,945	$ 105		970,207	(25,062)	3,668	533,027
Beginning Balance (in shares) at Dec. 31, 2022		105,138,273	50,433,101
Net loss	(15,972)
Net loss					(12,063)		(3,909)
Other comprehensive Income	(1,247)					(875)	(372)
Vested incentive units				(505)			505
Effect of LLC unit exchanges	(10,466)	$ 5		41,881			(52,352)
Effect of LLC unit exchanges, shares		4,771,545	(4,771,545)
Equity-based compensation	11,128			7,811			3,317
Forfeited unvested incentive units			(34,623)
Issuance of Class A Common Stock upon vesting of RSUs, shares		380,676
Issuance of Class A Common Stock upon vesting of RSUs				828			(828)
Shares withheld related to net share settlement (in shares)		(127,829)
Shares withheld related to net share settlement	(1,530)			(1,530)
Ending Balance at Mar. 31, 2023	1,463,858	$ 110		1,018,692	(37,125)	2,793	479,388
Ending Balance (in shares) at Mar. 31, 2023		110,162,665	45,626,933
Beginning Balance at Dec. 31, 2022	1,481,945	$ 105		970,207	(25,062)	3,668	533,027
Beginning Balance (in shares) at Dec. 31, 2022		105,138,273	50,433,101
Net loss	(276,265)
Net loss	(192,155)
Ending Balance at Sep. 30, 2023	1,203,450	$ 116		1,077,332	(217,217)	3,051	340,168
Ending Balance (in shares) at Sep. 30, 2023		116,281,962	39,781,946
Beginning Balance at Mar. 31, 2023	1,463,858	$ 110		1,018,692	(37,125)	2,793	479,388
Beginning Balance (in shares) at Mar. 31, 2023		110,162,665	45,626,933
Net loss	(11,605)
Net loss					(8,566)		(3,039)
Other comprehensive Income	635					459	176
Vested incentive units				(390)			390
Effect of LLC unit exchanges	(5,880)	$ 3		23,934			(29,817)
Effect of LLC unit exchanges, shares		2,718,054	(2,718,054)
Equity-based compensation	12,363			8,943			3,420
Distributions to noncontrolling interests	(2,827)						(2,827)
Forfeited unvested incentive units			(47,267)
Issuance of Class A Common Stock upon vesting of RSUs, shares		309,694
Issuance of Class A Common Stock upon vesting of RSUs				620			(620)
Shares withheld related to net share settlement (in shares)		(105,249)
Shares withheld related to net share settlement	(1,085)			(1,085)
Ending Balance at Jun. 30, 2023	1,455,459	$ 113		1,050,714	(45,691)	3,252	447,071
Ending Balance (in shares) at Jun. 30, 2023		113,085,164	42,861,612
Net loss	(248,688)
Net loss	(171,526)				(171,526)		(77,162)
Other comprehensive Income	(267)					(201)	(66)
Vested incentive units				(5,086)			5,086
Effect of LLC unit exchanges	(6,400)	$ 3		23,231			(29,634)
Effect of LLC unit exchanges, shares		3,057,466	(305,746)
Equity-based compensation	11,994			8,864			3,130
Distributions to noncontrolling interests	(7,866)						(7,866)
Forfeited unvested incentive units			(22,200)
Issuance of Class A Common Stock upon vesting of RSUs, shares		214,549
Issuance of Class A Common Stock upon vesting of RSUs				391			(391)
Shares withheld related to net share settlement (in shares)		(75,217)
Shares withheld related to net share settlement	(782)			(782)
Ending Balance at Sep. 30, 2023	$ 1,203,450	$ 116		$ 1,077,332	$ (217,217)	$ 3,051	$ 340,168
Ending Balance (in shares) at Sep. 30, 2023		116,281,962	39,781,946

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Cash flows provided by (used in) operating activities:
Net loss	$ (248,688)	$ (15,972)	$ (6,885)	$ (13,039)	$ (276,265)	$ (30,066)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization					1,391	1,721
Amortization of intangible assets					37,358	42,497
Amortization of deferred contract costs					9,475	6,274
Equity-based compensation					35,485	25,010
Amortization of debt issuance costs					527	527
Provision for doubtful accounts receivable					820	769
Non-cash restructuring charges					155	1,023
Goodwill impairment charge	287,400		0		287,400	0	$ 0
Tax receivable agreement remeasurement					(24,977)	(8,583)
Deferred income taxes					(19,728)	(719)
Changes in operating assets and liabilities:
Accounts receivable					19,370	12,454
Prepaid expenses and other current assets					(5,808)	2,554
Deferred contract costs					(13,020)	(10,070)
Contingent consideration					0	(6,400)
Accounts payable, accrued expenses and other liabilities					(1,589)	5,832
Deferred revenue					(14,113)	(3,024)
Net cash provided by operating activities					36,481	39,799
Cash flows (used in) provided by investing activities:
Purchases of property, equipment and other assets					(2,383)	(3,455)
Purchases of short-term investments					(213,613)	(217,266)
Maturities of short-term investments					174,830	96,000
Cash paid for acquisitions, net of cash acquired					(45,023)	(56,296)
Net cash used in investing activities					(86,189)	(181,017)
Cash flows used in financing activities:
Repayments of term loans					(5,156)	(5,156)
Taxes paid related to net share settlement of equity awards					(3,397)	(2,745)
Payment of contingent consideration					0	(1,100)
Payments under tax receivable agreement					(246)	0
Payments of equity offering issuance costs					(30)	(1,299)
Member distributions					(10,693)	(6,939)
Net cash used in financing activities					(19,522)	(17,239)
Net decrease in cash and cash equivalents					(69,230)	(158,457)
Effect of exchange rate changes on cash and cash equivalents					(244)	(213)
Cash and cash equivalents, beginning of period		$ 146,934		$ 387,498	146,934	387,498	387,498
Cash and cash equivalents, end of period	$ 77,460		$ 228,828		77,460	228,828	$ 146,934
Supplemental cash flow disclosures:
Interest					10,772	7,248
Income taxes					136	0
Acquisitions:
Net assets acquired, net of cash acquired					52,659	97,296
Working capital adjustment receivable					164	0
Initial cash investment in prior year					0	(40,000)
Contingent consideration					7,800	(1,000)
Net cash paid for acquisitions					45,023	56,296
Supplemental disclosure of non-cash investing activities:
Capital expenditures included in accounts payable and accrued expenses					283	4,504
Supplemental disclosure of non-cash financing activities:
Unpaid equity offering costs included in accrued expenses					$ 0	$ 147

Organization and Basis of Prese

Organization and Basis of Presentation	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	1. Organization and Basis of Presentation Description of Business and Organization Definitive Healthcare Corp. (the “Company”) was formed on May 5, 2021 as a Delaware corporation to facilitate an initial public offering (“IPO”) and other related transactions to carry on the business of AIDH TopCo, LLC (“Definitive OpCo”). Following consummation of the Reorganization Transactions as described in the Company’s 2022 Form 10-K/A, Definitive OpCo became a subsidiary of Definitive Healthcare Corp. The Company, through its operating subsidiaries, provides comprehensive and up-to-date hospital and healthcare-related information and insight across the entire healthcare continuum via a multi-tenant software-as-a-service (“SaaS”) platform which combines proprietary and public sources to deliver insights. The Company is headquartered in Framingham, Massachusetts. In connection with the IPO, the Company completed the following transactions (the “Reorganization Transactions”). Definitive OpCo entered into an amended and restated limited liability company agreement (the “Amended LLC Agreement”) pursuant to which members of Definitive OpCo prior to the IPO who continued to hold limited liability company interests (“LLC Units”) in Definitive OpCo following the consummation of the Reorganization Transactions acquired the right to require Definitive OpCo to redeem all or a portion of their LLC Units for newly issued shares of Class A Common Stock on a one-for-one basis. Until redeemed or exchanged, each LLC Unit is paired with one share of Definitive Healthcare Corp. Class B Common Stock. The total shares of Class B Common Stock outstanding is equal to the number of vested LLC Units outstanding, excluding LLC Units held by the Company. Unvested LLC Units are paired with Class B Common Stock, which are issued but do not have voting rights and are deemed not outstanding until the corresponding LLC Units have vested. Certain entities treated as corporations for U.S. federal income tax purposes that held LLC Units (individually, a “Blocker Company” and collectively, the “Blocker Companies”) each merged with a merger subsidiary of Definitive Healthcare Corp., and subsequently merged into Definitive Healthcare Corp. (the “Mergers”). The former shareholders of the Blocker Companies collectively received a number of shares of Class A Common Stock in the Mergers equal to the number of LLC Units held by the Blocker Companies prior to the Mergers. Following the Reorganization Transactions, Definitive Healthcare Corp. became a holding company, with its sole material asset being a controlling equity interest in Definitive OpCo. Definitive Healthcare Corp. operates and controls all of the business and affairs of Definitive OpCo, and through Definitive OpCo and its subsidiaries, conducts its business. Accordingly, Definitive Healthcare Corp. consolidates the financial results of Definitive OpCo, and reports the noncontrolling interests of unexchanged LLC Unit holders on its condensed consolidated financial statements. In connection with the Reorganization Transactions and the IPO, Definitive Healthcare Corp entered into a tax receivable agreement. See Note 15. Income Taxes . Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and in conformity with rules applicable to quarterly financial information. Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative nongovernmental GAAP as found in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”). The condensed consolidated financial statements as of September 30, 2023 and for the three and nine months ended September 30, 2023 and 2022 are unaudited and should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2022. All adjustments, consisting of normal recurring adjustments, except as otherwise noted, considered, in the opinion of management, necessary for a fair presentation of the unaudited interim condensed consolidated financial statements for these interim periods have been included. Refer to Note 2. Summary of Significant Accounting Policies in the notes to the consolidated financial statements in the 2022 Form 10-K/A for the Company’s significant accounting policies and estimates. Use of Estimates in the Preparation of Financial Statements The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting period. These estimates include, but are not limited to, revenue recognition, allowance for doubtful accounts, contingencies, valuations, useful lives of intangible assets acquired in business combinations, equity-based compensation, and income taxes. Actual results could differ from those estimates. Adoption of Recently Issued Financial Accounting Standards In June 2016, the FASB issued ASU No. 2016-13— Financial Instruments – Credit Losses (Topic 326) – Measurement of Credit Losses on Financial Instruments . This standard is intended to improve financial reporting by requiring earlier recognition of credit losses on financing receivables and other financial assets in scope, such as trade receivables. The amendment is effective for fiscal years beginning after December 15, 2022. The Company adopted the update effective January 1, 2023 and the adoption of the standard did not have a material impact on the Company's condensed consolidated financial statements for the quarter ended September 30, 2023. Recently Issued Accounting Pronouncements Not Yet Adopted From time to time, new accounting pronouncements are issued by the FASB or other accounting standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, we do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated statements or disclosures. Restatement of Previously Issued Financial Statements The financial statements for the three and nine months ended September 30, 2022, have been restated to reflect the correction of misstatements related to the collection of sales taxes from sales of services to customers further described below (the “Misstatements”), along with other immaterial adjustments. The Company also restated all amounts within the notes to the financial statements. A description of adjustments and their impact on the previously issued financial statements are included below. In the first quarter of 2023, the Company began a review of its sales tax positions, and related accounting matters, with the assistance of outside consultants. As a result of the review, the Company determined during the second quarter of 2023 that sales in certain states were subject to sales tax and that the Company had not assessed such sales tax on sales of its services to customers. The Company determined that it did not accrue sales taxes and corrected these Misstatements by recording sales tax accruals through general and administrative expense as of the end of each affected period. These accrual amounts assume that (i) customers who have not yet provided certificates or other documentation of exemption from sales tax are taxable, (ii) maximum interest and penalty assessments may be imposed, and (iii) the Company will not receive waivers of interest and penalties or other benefits under agreements it may obtain with jurisdictions from its outreach with voluntarily disclosures. The Company expects to make adjustments to the sales tax liability in future periods based on the results of the voluntary disclosure agreements, including, but not limited to, classification of exempt sales based on customer exemption certificates, waivers of interest and penalties, or other benefits. The Misstatements that appeared in the previously issued financial statements were material, and the Company has also corrected other immaterial errors, which are further described below. As described in additional detail in the Explanatory Note in our 2022 Form 10-K/A, the Company restated its audited consolidated financial statements as of and for the years ended December 31, 2022, 2021 and 2020, as well as the unaudited condensed consolidated quarterly financial information for the quarterly periods in the fiscal years ended December 31, 2022, 2021, and 2020, to reflect the correction of the Misstatements and other immaterial adjustments, and to make corresponding disclosures. The Company also filed an Amendment No. 1 on Form 10-Q/A to amend the Quarterly Report on Form 10-Q for the three months ended March 31, 2023 with the SEC on August 14, 2023, to restate its unaudited condensed consolidated financial statements for the three months ended March 31, 2023 and 2022. A summary of the impacts of the Misstatements and other immaterial adjustments is as follows: Three Months Ended September 30, 2022 Nine Months Ended September 30, 2022 (in thousands) As previously reported As Restated As previously reported As Restated Net loss $ ( 6,354 ) $ ( 6,885 ) $ ( 28,990 ) $ ( 30,066 ) Net loss attributable to noncontrolling interests ( 3,665 ) ( 3,865 ) ( 12,527 ) ( 12,979 ) Net loss attributable to Definitive Healthcare Corp. ( 2,689 ) ( 3,020 ) ( 16,463 ) ( 17,087 ) As of September 30, 2022 (in thousands) As previously reported As Restated Total assets $ 2,119,773 $ 2,121,404 Total liabilities 642,251 648,311 Total equity 1,477,522 1,473,093 The categories of restatement adjustments and their impacts on previously reported financial statements are described below: a) Sales Tax and Related Misstatements – Sales tax on sales of services to customers who were subject to sales tax, inclusive of maximum penalties and interest, that was not previously accrued by the Company is corrected by an increase to accrued expenses and other current liabilities on the condensed consolidated balance sheets and an increase to general and administrative expenses on the condensed consolidated statements of operations. b) Related Impact on Tax Receivable Agreement ( “ TRA ” ) – Any impact on tax receivable gains and losses due to the corrections in (a) above is reflected as a change in the tax receivable agreement liability on the balance sheet and a change in other expense on the condensed consolidated statements of operations. c) Purchase Price Allocation Misstatement – In connection with the Company’s acquisition of Monocl Holding Company, the Company had previously failed to record a deferred tax liability related to identified intangible assets of Monocl Holding Company. Therefore, the Company corrected the opening purchase price of Monocl Holding Company to record an opening deferred tax liability with an offset to goodwill on the condensed consolidated balance sheets. The opening deferred tax liability subsequently resulted in an increase in benefit from income taxes on the consolidated statements of operations through the period ending March 31, 2022. d) Related Impact on Noncontrolling Interests – Any impact on noncontrolling interests resulting from the allocation of net loss due to the corrections in (a) and (c) above is reflected as (i) a change in the net loss attributable to noncontrolling interests on the condensed consolidated statements of operations, and (ii) a change in noncontrolling interests on the condensed consolidated balance sheets. The following table sets forth the corrections in each of the line items affected in the consolidated statements of operations for each respective period: (in thousands) Three Months Ended September 30, 2022 Nine Months Ended Increase in general and administrative expense (a) $ 631 $ 1,876 Increase in gain on remeasurement of TRA liability (other income) (b) 100 287 Increase in benefit from income taxes (c) — 513 Increase in net loss due to restatement items 531 1,076 Increase in net loss attributable to noncontrolling interests due to restatement items (d) 200 452 Increase in net loss attributable to Definitive Healthcare Corp. due to restatement items 331 624 See footnote descriptions above Three Months Ended Nine Months Ended (in thousands, except share amounts and per share data) As previously reported As Restated As previously reported As Restated Revenue $ 57,382 $ 57,382 $ 162,054 $ 162,054 Cost of revenue: Cost of revenue exclusive of amortization 6,569 6,569 18,717 18,717 Amortization 3,155 3,155 14,113 14,113 Gross profit 47,658 47,658 129,224 129,224 Operating expenses: Sales and marketing 21,184 21,184 66,062 66,062 Product development 9,205 9,205 24,761 24,761 General and administrative 13,718 14,349 33,564 35,440 Depreciation and amortization 10,037 10,037 30,105 30,105 Transaction, integration, and restructuring expenses 2,945 2,945 6,362 6,362 Total operating expenses 57,089 57,720 160,854 162,730 Loss from operations ( 9,431 ) ( 10,062 ) ( 31,630 ) ( 33,506 ) Other income (expense), net: Interest income 608 608 858 858 Interest expense ( 3,074 ) ( 3,074 ) ( 7,788 ) ( 7,788 ) Other expense, net 5,528 5,628 9,429 9,716 Total other expense, net 3,062 3,162 2,499 2,786 Loss before income taxes ( 6,369 ) ( 6,900 ) ( 29,131 ) ( 30,720 ) Benefit from income taxes 15 15 141 654 Net loss ( 6,354 ) ( 6,885 ) ( 28,990 ) ( 30,066 ) Less: Net loss attributable to noncontrolling interests ( 3,665 ) ( 3,865 ) ( 12,527 ) ( 12,979 ) Net loss attributable to Definitive Healthcare Corp. $ ( 2,689 ) $ ( 3,020 ) $ ( 16,463 ) $ ( 17,087 ) Net loss per share of Class A Common Stock: Basic and diluted $ ( 0.03 ) $ ( 0.03 ) $ ( 0.16 ) $ ( 0.17 ) Weighted average Common Stock outstanding: Basic and diluted (1) 102,904,565 102,904,565 99,776,742 99,776,742 The following table sets forth the corrections in each of the line items affected in the condensed consolidated balance sheets for September 30, 2022: (in thousands) As previously reported Restatement Adjustments As Restated Goodwill 1,322,959 1,631 1,324,590 Total assets 2,119,773 1,631 2,121,404 Accrued expenses and other current liabilities 18,885 7,203 26,088 Total current liabilities 121,552 7,203 128,755 Tax receivable agreements liability, net of current portion 157,175 ( 1,143 ) 156,032 Total liabilities 642,251 6,060 648,311 Additional paid-in capital 962,874 ( 1,873 ) 961,001 Accumulated deficit ( 34,140 ) ( 787 ) ( 34,927 ) Noncontrolling interests 544,772 ( 1,769 ) 543,003 Total equity 1,477,522 ( 4,429 ) 1,473,093 Total liabilities and equity 2,119,773 1,631 2,121,404 The following table sets forth the corrections in each of the line items affected in the condensed consolidated statements of changes in total equity for September 30, 2022: Additional Paid-In Accumulated Noncontrolling Total (in thousands) Capital Deficit Interests Equity As reported $ 962,874 $ ( 34,140 ) $ 544,772 $ 1,477,522 Adjustment due to cumulative error correction ( 1,873 ) ( 787 ) ( 1,769 ) ( 4,429 ) As restated $ 961,001 $ ( 34,927 ) $ 543,003 $ 1,473,093 The Company did not present tables for quarterly adjustments within the consolidated statements of cash flows since all of the foregoing adjustments only affected financial statement line items within cash flows from operating activities. The adjustments did not affect total cash flows from operating activities, financing activities, or investing activities for any period presented.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2023
Business Combinations [Abstract]
Acquisitions	2. Acquisitions Populi, Inc. On July 21, 2023, the Company completed the acquisition of Populi, Inc. (“Populi”), a provider-focused data and analytics company that works with healthcare organizations to optimize physician relationships, reduce network leakage, and expand market share, for total estimated consideration of $ 54.1 million, consisting of approximately $ 46.4 million of cash paid at closing, $ 0.2 reimbursement from sellers for working capital adjustments, and up to $ 28.0 million of contingent consideration, with an initial estimated fair value of $ 7.8 million. The contingent consideration relates to earn-out payments that may be paid subject to meeting certain revenue metrics during calendar years 2024 and 2025. In addition to the purchase consideration and pursuant to holdback agreements with certain key Populi employees, the Company agreed to pay $ 4.8 million to certain key Populi employees in quarterly installments beginning on December 31, 2023, and continuing through September 30, 2025. The payout of the holdback is subject to continued employment, and therefore recognized as compensation expense over the requisite service period as a component of transaction, integration and restructuring expenses in the accompanying condensed consolidated statements of operations. The assets acquired and liabilities assumed were recorded at their estimated fair values and the results of operations were included in the Company’s consolidated results as of the acquisition date. The consideration transferred for the transaction is summarized as follows: (in thousands) Cash consideration paid at closing $ 46,446 Working capital adjustment ( 164 ) Contingent consideration 7,800 Purchase price $ 54,082 The contingent consideration is based on the achievement of certain revenue metrics during the two-year period following the acquisition date, with potential earn-out payouts ranging from $ 0 to $ 28.0 million. The Company estimated the fair value of the contingent consideration to be $ 7.8 million as of July 21, 2023, based on the estimated achievement of the revenue metrics and time to payment. The contingent consideration was recorded in Other liabilities in the accompanying condensed consolidated balance sheet as of September 30, 2023. Refer to Note 11. Fair Value Measurements . The purchase price allocations for the Populi acquisition are provisional and are based on the information that was available as of the acquisition date to estimate the fair values of assets acquired and liabilities assumed. The Company is gathering and reviewing additional information necessary to finalize the values assigned to the acquired assets and liabilities assumed, as well as acquired identified intangible assets and goodwill. Therefore, the provisional measurements of fair values reported as of September 30, 2023 are subject to change. The Company is expected to finalize the purchase price allocations as soon as practicable, but no later than one year from the acquisition date. Acquisition-date fair values of assets and liabilities pertaining to this business combination have been allocated as follows: (in thousands) Purchase price allocation: Preliminary Cash $ 1,423 Accounts receivable 2,662 Prepaid expenses and other current assets 153 Property and equipment 42 Intangible assets 22,830 Accounts payable and accrued expenses ( 3,316 ) Deferred revenue ( 4,010 ) Other liabilities ( 2,354 ) Total assets acquired and liabilities assumed 17,430 Goodwill 36,652 Purchase price $ 54,082 As a result of the Populi acquisition, the Company recorded goodwill, developed software, customer relationships, and tradename of $ 36.7 million, $ 21.4 million, $ 1.3 million, and $ 0.1 million, respectively, as of the acquisition date. The goodwill recognized includes the fair value of the assembled workforce, which is not recognized as an intangible asset separable from goodwill, and any expected synergies gained through the acquisition. The Company determined that the goodwill resulting from the acquisition is not deductible for tax purposes. All goodwill has been allocated to the Company’s one reportable segment. The developed software represents Populi’s proprietary solutions that are designed to assist organizations in optimizing physician relationships, reducing network leakage, and expanding market share. The Company used the income approach, specifically the multi-period excess earnings method, to determine the value of developed software. Significant assumptions include an obsolescence factor, tax rate, and discount rate. The developed software was valued at $ 21.4 million and is amortized using the economic value method, which represents the pattern of cash flows over the estimated 7-year life of this asset. Customer relationships represent the estimated fair value of the underlying relationships with the acquired entity’s business customers. The Company valued customer relationships using the income approach, specifically the multi-period excess earnings method. Significant assumptions include estimated attrition rates, discount rates, and tax rates reflecting the different risk profiles of the asset depending upon the acquisition. The value assigned to customer relationships is $ 1.3 million and is amortized using the straight-line method over the estimated remaining useful life of 20 years . The tradename represents the estimated fair value of the registered trade name associated with the Populi corporate brand. The Company estimated the fair value of the trademark using a relief from royalty method of the income approach. Significant assumptions include forecast of royalty rate, tax rate, and discount rate. The trademark was valued at $ 0.1 million and is amortized using the straight-line method over the estimated remaining useful life of 1 year . The amortization periods for the developed software, customer relationships, and tradenames are 7 years , 20 years , and 1 year , respectively. See Note 7 for the estimated total intangible amortization expense during the next five years. In connection with the acquisition, the Company recognized acquisition related costs of $ 4.4 million which were recorded within t ransaction, integration, and restructuring expenses in the accompanying condensed consolidated statements of operations for the nine months ended September 30, 2023. Unaudited Pro Forma Supplementary Data as if the transaction had occurred on January 1, 2022: Nine Months Ended September 30, 2023 2022 (in thousands) Revenue $ 189,697 $ 166,204 Net loss ( 280,870 ) ( 36,423 ) These pro forma results have been prepared for comparative purposes only and do not purport to be indicative of the operating results of the Company that would have been achieved had the acquisition actually taken place on January 1, 2022. In addition, these results are not intended to be a projection of future results and do not reflect events that may occur after the acquisition, including but not limited to revenue enhancements, cost savings or operating synergies that the combined Company may achieve as a result of the acquisition. Analytical Wizards On December 22, 2021, Definitive Healthcare, LLC (“DH, LLC”), an indirect wholly owned subsidiary of Definitive Healthcare Corp. made a $ 40.0 million investment in Analytical Wizards Inc. (“AW” or “Analytical Wizards”), a privately held company. Analytical Wizards automates complex analytic models using tools that expedite efficient big data mining through artificial intelligence and machine learning to uncover deep insights. In the transaction the Company purchased Series B Convertible Preferred Stock of AW (“Series B Preferred Stock”), representing 35 % ownership of AW, and an option to acquire the remaining 65 % ownership (the "Purchase Option") for $ 65.0 million. As of December 31, 2021, the Company determined it did not have a controlling financial interest in AW at transaction close as the Company did not have the right to control the governing body of AW or have control through other contractual rights. At December 31, 2021, because the Series B Preferred Stock and the Purchase Option did not have readily determinable fair values, the Company elected to apply the measurement alternative and adjust the carrying value of the investments in AW for impairments and observable prices in identical or similar equity securities of AW. The Company paid $ 40.0 million for the Series B Preferred Stock and Purchase Option, which was allocated on a relative fair value basis such that the Series B Preferred Stock and Purchase Option had carrying values of $ 32.7 million and $ 7.3 million at the time of the transaction, respectively. The Series B Preferred Stock was recorded in Investments in equity securities and the Purchase Option was recorded in Other assets in the accompanying condensed consolidated balance sheet as of December 31, 2021. In February 2022, the Company completed the purchase the remaining 65 % of AW’s equity for $ 65.0 million, net of cash acquired and an estimated working capital adjustment and other customary purchase price adjustments (the “AW acquisition”). The Company’s previously held investment and Purchase Option were remeasured at fair value as of the date the Purchase Option was exercised. The remeasurement had an immaterial impact on the condensed consolidated statements of operations for the three months ended March 31, 2022. The Company has included the financial results of Analytical Wizards in the condensed consolidated financial statements from February 18, 2022 , the date of acquisition. Upon the consummation of the acquisition, AW became an indirect wholly owned subsidiary of Definitive Healthcare Corp. The total consideration for the initial investment and subsequent exercise of the Purchase Option was $ 99.4 million, consisting of $ 40.0 million for the initial investment paid in December 2021, approximately $ 58.6 million of cash paid at closing, $ 0.2 million reimbursement from sellers for working capital adjustments, and up to $ 5.0 million of contingent consideration, initially valued at $ 1.0 million. The contingent consideration, which relates to earn-out payments that may be paid out, subject to meeting certain expense control metrics during the two-year period following the closing of the AW acquisition, has an estimated fair value of $ 1.0 million as of the acquisition date. Pursuant to the Stock Purchase Agreement governing the AW acquisition, $ 10.0 million of the consideration was deposited into an escrow account to secure certain indemnification claims of DH, LLC. The assets acquired and liabilities assumed were recorded at their estimated preliminary fair values and the results of operations were included in the Company’s condensed consolidated results as of the acquisition date. The consideration transferred for the transaction is summarized as follows: (in thousands) Initial cash investment in December 2021 $ 40,000 Cash consideration paid at closing 58,645 Working capital adjustment ( 202 ) Contingent consideration 1,000 Purchase price $ 99,443 The contingent consideration was based on the achievement of certain expense control metrics during the two-year period following the acquisition date, with potential earn-out payouts ranging from $ 0 to $ 5.0 million. The Company estimated the fair value of the contingent consideration to be $ 1.0 million as of February 18, 2022, based on the estimated achievement of the expense control metrics and time to payment. The Company estimated the fair value of the contingent consideration to be $ 2.3 million at September 30, 2023. The contingent consideration was recorded in accrued expenses and other current liabilities in the accompanying condensed consolidated balance sheet as of September 30, 2023. Refer to Note 11. Fair Value Measurements . The Company finalized the purchase price allocations of the AW acquisition during the first quarter of 2023. Acquisition-date fair values of assets and liabilities pertaining to this business combination have been allocated as follows: (in thousands) Purchase price allocation: Preliminary, as originally reported Measurement period adjustments As adjusted Cash $ 2,146 $ — $ 2,146 Accounts receivable 3,575 ( 50 ) 3,525 Prepaid expenses and other current assets 506 341 847 Property and equipment 134 — 134 Intangible assets 46,000 — 46,000 Right-of-use asset, operating leases 832 — 832 Other assets — 703 703 Accounts payable and accrued expenses ( 485 ) ( 543 ) ( 1,028 ) Deferred revenue ( 3,691 ) 326 ( 3,365 ) Right-of-use liability, operating leases ( 832 ) — ( 832 ) Deferred taxes ( 10,345 ) 67 ( 10,278 ) Other liabilities ( 267 ) ( 633 ) ( 900 ) Total assets acquired and liabilities assumed 37,573 211 37,784 Goodwill 62,072 ( 413 ) 61,659 Purchase price $ 99,645 $ ( 202 ) $ 99,443 As a result of the AW acquisition, the Company recorded goodwill, customer relationships, developed software, and tradename of $ 61.5 million, $ 39.4 million, $ 6.1 million, and $ 0.5 million, respectively, as of the acquisition date. The goodwill recognized includes the fair value of the assembled workforce, which is not recognized as an intangible asset separable from goodwill, and any expected synergies gained through the acquisition. The Company determined that the goodwill resulting from the acquisition is not deductible for tax purposes. All goodwill has been allocated to the Company’s one reportable segment. Customer relationships represent the estimated fair value of the underlying relationships with the acquired entity’s business customers. The Company valued customer relationships using the income approach, specifically the multi-period excess earnings method. Significant assumptions include estimated attrition rates, discount rates, and tax rates reflecting the different risk profiles of the asset depending upon the acquisition. The value assigned to customer relationships is $ 39.4 million and is amortized using the annual pattern of cash flows (economic value method) over the estimated 20-year life of this asset. The developed software represents AW’s two modules. Passport Promotional Analytics helps customers to optimize internal investment and business management by focusing on driving incremental efficiencies in sales, cost management, profit optimization, and productive gains. Passport Planning and Performance helps customers to analyze large data sets in order to proactively predict business outcomes. The Company used the income approach, specifically the relief-from-royalty method, to determine the value of developed software. Significant assumptions include forecast of royalty rate, tax rate, and discount rate. The developed software was valued at $ 6.1 million and is amortized using the straight-line method over the estimated remaining useful life of 6 years . The tradename represents the estimated fair value of the registered trade name associated with the AW corporate brand. The Company estimated the fair value of the trademark using a relief from royalty method of the income approach. Significant assumptions include forecast of royalty rate, tax rate, and discount rate. The trademark was valued at $ 0.5 million and is amortized using the straight-line method over the estimated remaining useful life of 5 years . The amortization periods for the customer relationships, developed software, and tradenames are 20 years , 6 years , and 5 years , respectively. See Note 7 for the estimated total intangible amortization expense during the next five years. In connection with the acquisition, the Company recognized acquisition related costs of $ 1.3 million which were recorded within transaction expenses in the accompanying condensed consolidated statements of operations for the year ended December 31, 2022. During the nine months ended September 30, 2022, AW’s post-acquisition revenue and net loss on a standalone basis were not material. Unaudited Pro Forma Supplementary Data: Nine Months Ended September 30, 2022 (in thousands) (As Restated) Revenue $ 163,531 Net loss ( 29,566 ) The unaudited pro forma supplementary data presented in the table above shows the effect of the AW acquisitions as if the transaction had occurred on January 1, 2022.

Revenue

Revenue	9 Months Ended
	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue	3. Revenue The Company disaggregates revenue from its arrangements with customers by type of service as it believes these categories best depict how the nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factors. The following table represents a disaggregation of revenue from arrangements with customers for the three and nine months ended September 30, 2023 and 2022, respectively: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Subscription services $ 62,568 $ 56,156 $ 180,358 $ 159,136 Professional services 2,757 1,226 5,125 2,918 Total revenue $ 65,325 $ 57,382 $ 185,483 $ 162,054 The opening and closing balances of the Company’s receivables, deferred contract costs and contract liabilities from contracts with customers are as follows: (in thousands) September 30, December 31, Accounts receivable, net $ 41,308 $ 58,799 Deferred contract costs, current portion 12,396 10,387 Deferred contract costs, long-term 16,132 14,596 Deferred revenues 89,781 99,928 Deferred Contract Costs A summary of the activity impacting the deferred contract costs for the nine months ended September 30, 2023 and the year ended December 31, 2022 is presented below: (in thousands) Nine Months Ended September 30, 2023 Twelve Months Ended December 31, 2022 Balance at beginning of period $ 24,983 $ 18,547 Costs amortized ( 9,475 ) ( 8,816 ) Additional amounts deferred 13,020 15,252 Balance at end of period 28,528 24,983 Classified as: Current 12,396 10,387 Non-current 16,132 14,596 Total deferred contract costs (deferred commissions) $ 28,528 $ 24,983 Contract Liabilities A summary of the activity impacting deferred revenue balances during the nine months ended September 30, 2023 and for the year ended December 31, 2022 is presented below: (in thousands) Nine Months Ended September 30, 2023 Twelve Months Ended December 31, 2022 Balance at beginning of period $ 99,928 $ 84,023 Revenue recognized ( 185,483 ) ( 222,653 ) Additional amounts deferred 175,336 238,558 Balance at end of period $ 89,781 $ 99,928 Remaining Performance Obligations Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes unearned revenue and unbilled amounts that will be invoiced and recognized as revenue in future periods. Transaction price allocated to remaining performance obligations is influenced by several factors, including seasonality, the timing of renewals, and disparate contract terms. The Company’s backlog represents installment billings for periods beyond the current billing cycle. The majority of the Company’s noncurrent remaining performance obligations will be recognized in the next 13 to 36 months. The remaining performance obligations consisted of the following: (in thousands) September 30, December 31, Current $ 170,782 $ 183,527 Non-current 82,462 93,464 Total $ 253,244 $ 276,991

Short-term Investments

Short-term Investments	9 Months Ended
	Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Short-term Investments	4. Short-term Investments Short-term investments classified as available-for-sale consisted of the following: September 30, 2023 (in thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Short-term investments: US Treasuries $ 96,668 $ — $ ( 197 ) $ 96,471 Agency bonds 1,107 — — 1,107 Corporate Bonds 2,280 — — 2,280 Commercial paper 104,719 1 ( 74 ) 104,646 Certificates of deposit 25,072 3 ( 14 ) 25,061 Total short-term investments $ 229,846 $ 4 $ ( 285 ) $ 229,565 December 31, 2022 (in thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Short-term investments: US Treasuries $ 59,849 $ 3 $ ( 129 ) $ 59,723 Agency bonds 6,450 4 ( 2 ) 6,452 Commercial paper 95,831 29 ( 123 ) 95,737 Certificates of deposit 23,034 17 ( 24 ) 23,027 Total short-term investments $ 185,164 $ 53 $ ( 278 ) $ 184,939 All short-term investments had stated maturity dates of less than one year.

Accounts Receivable

Accounts Receivable	9 Months Ended
	Sep. 30, 2023
Receivables [Abstract]
Accounts Receivable	5. Accounts Receivable Accounts receivable consisted of the following: (in thousands) September 30, December 31, Accounts receivable $ 42,037 $ 59,780 Unbilled receivable 959 881 42,996 60,661 Less: allowance for doubtful accounts ( 1,688 ) ( 1,862 ) Accounts receivable, net $ 41,308 $ 58,799

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment	6. Property and Equipment Property and equipment consisted of the following: (in thousands) September 30, December 31, Computers and software $ 7,003 $ 5,924 Furniture and equipment 1,420 1,204 Leasehold improvements 2,283 2,134 10,706 9,262 Less: accumulated depreciation and amortization ( 6,078 ) ( 4,798 ) Property and equipment, net $ 4,628 $ 4,464 Depreciation and amortization expense associated with property and equipment was $ 0.4 million and $ 0.5 million for the three months ended September 30, 2023 and 2022 , respectively, and $ 1.3 million and $ 1.7 million for the nine months ended September 30, 2023 and 2022 , respectively.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	7. Goodwill and Intangible Assets The carrying amounts of goodwill and intangible assets, as of September 30, 2023 and December 31, 2022, consisted of the following: September 30, 2023 (in thousands) Gross Accumulated Net Carrying Finite-lived intangible assets: Customer relationships $ 410,710 $ ( 154,789 ) $ 255,921 Developed technologies 78,324 ( 31,627 ) 46,697 Tradenames 36,021 ( 8,775 ) 27,246 Database 50,204 ( 44,041 ) 6,163 Total finite-lived intangible assets 575,259 ( 239,232 ) 336,027 Goodwill 1,073,986 — 1,073,986 Total goodwill and intangible assets $ 1,649,245 $ ( 239,232 ) $ 1,410,013 December 31, 2022 Gross Accumulated Net Carrying (in thousands) (As Restated) Finite-lived intangible assets: Customer relationships $ 409,430 $ ( 128,745 ) $ 280,685 Developed technologies 56,965 ( 25,514 ) 31,451 Tradenames 35,914 ( 7,150 ) 28,764 Database 50,215 ( 40,393 ) 9,822 Total finite-lived intangible assets 552,524 ( 201,802 ) 350,722 Goodwill 1,324,733 — 1,324,733 Total goodwill and intangible assets $ 1,877,257 $ ( 201,802 ) $ 1,675,455 Amortization expense associated with finite-lived intangible assets wa s $ 12.6 m illion and $ 12.7 million for the three months ended September 30, 2023 and 2022 , respectively, of which $ 3.2 million was included in cost of revenue for each period. Amortization expense associated with finite-lived intangible assets wa s $ 37.4 m illion and $ 42.5 million for the nine months ended September 30, 2023 and 2022 , respectively, of which $ 9.7 million and $ 14.1 million was included in cost of revenue for the respective periods. Estimated total intangible amortization expense during the next five years and thereafter is as follows: (in thousands) 2023, excluding the nine months ended September 30, 2023 $ 12,479 2024 48,455 2025 45,945 2026 39,305 2027 33,357 Thereafter 156,486 Total $ 336,027 The Company determined it had one reporting unit. Goodwill Impairment Goodwill and acquired intangible assets are initially recorded at fair value and tested periodically for impairment. The Company performs an impairment test of goodwill during the fourth quarter of each fiscal year and more frequently if indicators of potential impairment arise. During the three months ended September 30, 2023, the Company experienced a decline in its market capitalization as a result of a sustained decrease in the Company’s stock price, which represented a triggering event requiring management to perform a quantitative goodwill impairment test as of September 30, 2023. As a result of the impairment test, the Company determined that the fair value of its single reporting unit was lower than its carrying value and, accordingly, recorded a non-cash, pretax, goodwill impairment charge of $ 287.4 million. The goodwill impairment charge did not affect the Company’s liquidity or the financial covenants in any of its outstanding debt agreements. In calculating the goodwill impairment charge, the Company estimated the fair value of its single reporting unit using a combination of an income and market approach. The income approach utilizes a discounted cash flow model associated with the business, including the amount and timing of future expected cash flows, tax attributes, technology and customer attrition rates, a terminal value growth rate, and an appropriate market-participant, risk-adjusted, weight average cost of capital in each case using estimates that the Company considered to be reasonable and appropriate. The market approach utilizes the Company's market capitalization, plus an appropriate control premium. Market capitalization is determined by multiplying the number of shares of Class A Common Stock outstanding by the market price of its Class A Common Stock. The control premium is determined by utilizing data from publicly available premium studies for similarly situated public company transactions. A goodwill impairment loss is recognized for the difference between the carrying value of the reporting unit and the fair value. As of September 30, 2023 and December 31, 2022, goodwill consisted of the following: (in thousands) Nine Months Ended Twelve Months Ended Goodwill - beginning of period $ 1,324,733 $ 1,263,075 Goodwill acquired during period 36,653 61,658 Goodwill impairment loss ( 287,400 ) — Goodwill - end of period $ 1,073,986 $ 1,324,733 The Company also considered its intangible assets with finite useful lives, which are amortized over their estimated useful lives, generally on a straight-line basis. These assets are reviewed for impairment when facts or circumstances indicate that the carrying values may not be recoverable. The decline in the Company’s market capitalization driven by a sustained decrease in the Company’s stock price was considered to represent a triggering event and the Company’s intangible assets were reviewed for impairment. Based on quantitative and qualitative analyses performed, management concluded the assets were recoverable and no impairment charge was recorded.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2023
Accounts Payable and Accrued Liabilities, Current [Abstract]
Accrued Expenses and Other Current Liabilities	8. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following: September 30, December 31, (in thousands) (As Restated) Payroll and payroll-related $ 10,503 $ 11,961 Tax receivable agreement, current portion 6,673 — Contingent consideration, current 2,250 — Sales, franchise, and other taxes 11,352 11,738 Other 5,208 3,156 Accrued expenses and other current liabilities $ 35,986 $ 26,855 During the first and third quarters of 2023, the Company announced restructuring plans intended to reduce operating costs, improve operating margins, and continue advancing the Company’s ongoing commitment to profitable growth. During the three and nine months ended September 30, 2023, the Company incurred restructuring and related charges of $ 2.1 million and $ 4.6 million, respectively, consisting primarily of severance payments, employee benefits, and related cash expenses. These charges were recognized within Transaction, integration, and restructuring expenses in the Company’s condensed consolidated statements of operations. As of September 30, 2023 , $ 0.5 million is included in accrued expenses and other liabilities in the condensed consolidated balance sheets. The Company expects these payments will be made over the next three months. In addition, the Company does not expect to incur any further material charges associated with the restructuring plans. In the first quarter of 2023, the Company began a review of its sales tax positions, and related accounting matters, with the assistance of outside consultants. As a result of the review, the Company determined during the second quarter of 2023 that sales in certain states were subject to sales tax and that the Company had not assessed such sales tax on sales of its services to customers. As of September 30, 2023 and December 31, 2022, the Company has recorded a sales tax accrual, which includes assumed maximum penalties and interest of $ 9.2 million and $ 8.1 million, respectively.

Long-Term Debt

Long-Term Debt	9 Months Ended
	Sep. 30, 2023
Long-Term Debt, Unclassified [Abstract]
Long-Term Debt	9. Long-Term Debt Long-term debt consisted of the following as of September 30, 2023 and December 31, 2022, respectively: September 30, 2023 (in thousands) Principal Unamortized debt Total debt, 2021 Term Loan $ 261,250 $ ( 1,634 ) $ 259,616 Less: current portion of long-term debt 13,750 Long-term debt $ 245,866 December 31, 2022 (in thousands) Principal Unamortized debt Total debt, 2021 Term Loan $ 266,406 $ ( 2,047 ) $ 264,359 Less: current portion of long-term debt 8,594 Long-term debt $ 255,765 During the nine months ended September 30, 2023, the Company repaid $ 5.2 million in outstanding principal of the 2021 Term Loan (as defined below). 2021 Credit Agreement In September 2021, DH Holdings entered into a credit agreement (the “2021 Credit Agreement” ) with Bank of America, N.A., as administrative agent, the other lenders party thereto and the other parties specified therein. The 2021 Credit Agreement provides for (i) a $ 275.0 million term loan A facility (the “2021 Term Loan” ) and (ii) a $ 75.0 million revolving credit facility (the “2021 Revolving Line of Credit” and, together with the 2021 Term Loan, collectively, the “2021 Credit Facilities” ), the proceeds of which were used to repay a portion of the indebtedness outstanding under a previous credit agreement. Both the 2021 Term Loan and the 2021 Revolving Line of Credit mature on September 17, 2026 . The 2021 Credit Facilities include customary affirmative, negative, and financial covenants. The 2021 Credit Facilities are guaranteed by all of DH Holdings' wholly owned domestic restricted subsidiaries and AIDH Buyer, LLC, a Delaware limited liability company and the direct parent company of DH Holdings, in each case, subject to customary exceptions, and are secured by a lien on substantially all of the assets of DH Holdings and the guarantors, including a pledge of the equity of DH Holdings, in each case, subject to customary exceptions. The 2021 Term Loan is subject to annual amortization of principal, payable in equal quarterly installments on the last day of each fiscal quarter, commencing on December 31, 2021 (the “Initial Amortization Date” ), equal to approximately 2.5% per annum of the principal amount of the term loans in the first year and second year after the Initial Amortization Date and approximately 5.0% per annum of the principal amount of the term loans in the third year, fourth year, and fifth year after the Initial Amortization Date. A balloon payment of approximately $ 220.0 million will be due at the maturity of the 2021 Term Loan. There wa s $ 261.3 million outstanding on the 2021 Term Loan at September 30, 2023. DH Holdings is required to pay the lenders under the 2021 Credit Agreement an unused commitment fee of between 0.25 % and 0.30 % per annum on the undrawn commitments under the 2021 Revolving Line of Credit, depending on the total net leverage ratio, quarterly in arrears. The expense is included in interest expense in the statements of operations. There was no outstanding balance on the 2021 Revolving Line of Credit at September 30, 2023. For both the 2021 Term Loan and 2021 Revolving Line of Credit, DH Holdings may elect from several interest rate options based on the LIBO Rate or the Base Rate plus an applicable margin. The applicable margin is based on the total leverage ratio beginning in the fiscal year ended December 31, 2022. As of September 30, 2023 , the effective interest rate was 7.17 %. On October 31, 2022, the Company amended the 2021 Credit Agreement to replace the LIBO rate with Term Secured Overnight Financing Rate (“SOFR”) plus an applicable rate. In connection with the 2021 Credit Agreement, the Company capitalized financing costs totaling $ 3.5 million, $ 2.8 million for the 2021 Term Loan facility and $ 0.8 million for the 2021 Revolving Line of Credit. The financing costs associated with the 2021 Term Loan facility are recorded as a contra-debt balance in Term loan, net of current portion in the condensed consolidated balance sheets and are amortized over the remaining life of the loan using the effective interest method. The financing costs associated with the 2021 Revolving Line of Credit are recorded in Other assets in the condensed consolidated balance sheet are amortized over the life of the arrangement. At September 30, 2023 , the unamortized financing costs were $ 0.4 million.

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	9 Months Ended
	Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities	10. Derivative Instruments and Hedging Activities Risk Management Objective of Using Derivatives The Company is exposed to risks from changes in interest rates related to the 2021 Term Loan (See Note 9. Long-Term Debt ). The Company uses derivative financial instruments, specifically, interest rate swap contracts, in order to manage its exposure to interest rate movements. Interest rate swaps designated as cash flow hedges involve the receipt of variable amounts from a counterparty in exchange for the Company making fixed-rate payments over the life of the agreements without exchange of the underlying notional amount. Our primary objective in holding derivatives is to reduce the volatility of cash flows associated with changes in interest rates. The Company does not enter into derivative transactions for speculative or trading purposes. Cash Flow Hedges of Interest Rate Risk The Company entered into two interest rate swap agreements, effective on March 31, 2022. Until October 31, 2022, the counterparties to each of the agreements paid the Company interest at a floating rate on the notional amounts based on the one-month USD-LIBOR swap rate. On October 31, 2022, in conjunction with the amendment to the 2021 Credit Agreement (See Note 9. Long-Term Debt ), the Company amended the two interest rate swap agreements to replace the LIBO rate with Term SOFR. As a result, subsequent to October 31, 2022, the counterparties paid and will continue to pay interest at a floating rate based on Term SOFR. As of September 30, 2023 , the two outstanding interest rate swap agreements each had a notional value of $ 65.3 million with fixed interest rate s of 1.90650 % and 1.90900 %. Inter est payments under the swaps are made monthly on a net settlement basis. The Company has not recorded any amounts due to ineffectiveness for the period ended September 30, 2023 . The notional value of each interest rate swap agreement is expected to match the corresponding principal amount of a portion of our borrowings under the 2021 Term Loan. The swap agreements mature on March 31, 2025 . The derivative interest rate swaps are designated and qualify as cash flow hedges. Consequently, the change in the estimated fair value of the effective portion of the derivative is recognized in accumulated other comprehensive income (“AOCI”) on our consolidated balance sheets and reclassified to interest expense, net, when the underlying transaction has an impact on earnings. The Company expects to recognize approximately $ 4.3 million of net pre-tax gains from accumulated other comprehensive income as a reduction of interest expense in the next twelve months associated with its interest rate swaps. The Company recognizes derivative instruments and hedging activities on a gross basis as either assets or liabilities on the Company’s consolidated balance sheets and measures them at fair value. Hedge accounting generally provides for the matching of the timing of gain or loss recognition on the hedging instrument with the earnings effect of the hedged forecasted transactions in a cash flow hedge. To receive hedge accounting treatment, all hedging relationships are formally documented at the inception of the hedge, and the hedges must be highly effective in offsetting changes to future cash flows on hedged transactions. The fair values of the interest rate swaps and their respective locations in our condensed consolidated balance sheets at September 30, 2023 and December 31, 2022 were as follows: (in thousands) Description Balance Sheet Location September 30, 2023 December 31, 2022 Short-term derivative asset Prepaid expenses and other current assets $ 4,266 $ 3,716 Long-term derivative asset Other assets 1,600 2,834

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	11. Fair Value Measurements ASC 820, Fair Value Measurements and Disclosures (“ASC 820”), defines fair value as the price that would be received for an asset, or paid to transfer a liability, in an orderly transaction between market participants on the measurement date, and establishes a three-level fair value hierarchy that prioritizes the inputs used to measure fair value as follows: Level 1 - Observable inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities. Level 2 - Other inputs that are directly or indirectly observable in the marketplace. Level 3 - Unobservable inputs that are supported by little or no market activity, including the Company’s own assumptions in determining fair value. The Company’s financial assets and liabilities subject to the three-level fair value hierarchy consist principally of cash and equivalents, short-term investments, accounts receivable, accounts payable, long-term and short-term debt, and contingent consideration payable. The estimated fair value of cash included in cash and cash equivalents, accounts receivable, and accounts payable approximates their carrying value due to due to their short maturities (less than 12 months). Debt The Company’s short- and long-term debt are recorded at their carrying values in the condensed consolidated balance sheets, which may differ from their respective fair values. The carrying values and estimated fair values of the Company’s short- and long-term debt approximate their carrying values as of September 30, 2023 and December 31, 2022, based on interest rates currently available to the Company for similar borrowings. Money market funds (included in cash and cash equivalents) Money market funds are recorded at fair value using quoted market prices in active markets and are classified as Level 1 in the fair value hierarchy. Short-term investments The Company estimates the fair values of investments in U.S. treasuries, agency bond securities, commercial paper, and certificates of deposit using level 2 inputs, taking into consideration valuations obtained from a third-party pricing service. The pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, market yield curves, benchmark securities, prepayment/default projections based on historical data, and other observable inputs. Derivative financial instruments Currently, the Company uses interest rate swaps to manage interest rate risk. The valuation of these instruments is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each derivative. This analysis reflects the contractual terms of the derivatives, including the period to maturity, and uses observable market-based inputs, including interest rate curves, and implied volatilities. To comply with the provisions of ASC 820, the Company incorporates credit valuation adjustments to appropriately reflect both its own nonperformance risk and the respective counterparty’s nonperformance risk in the fair value measurements. Although the Company has determined that the majority of the inputs used to value its derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivatives utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by the Company and its counterparties. The Company has determined that the significance of the impact of the credit valuation adjustments made to its derivative contracts, which determination was based on the fair value of each individual contract, was not significant to the overall valuation. As a result, all of its derivatives held as of September 30, 2023 and December 31, 2022 were classified as Level 2 in the fair value hierarchy. Contingent consideration The deferred consideration resulting from the acquisition of Populi in the third quarter of 2023, which is subject to meeting certain revenue metrics during calendar years 2024 and 2025, is measured at fair value on a recurring basis. The fair value was estimated based on the present value of the amount expected to be paid at the end of the measurement period. At September 30, 2023, the fair value of the contingent consideration was estimated to be $ 7.8 million and was included in other long-term liabilities on the condensed consolidated balance sheets. The deferred consideration that resulted from the acquisition of Analytical Wizards in the first quarter of 2022, which is subject to the meeting of certain expense control metrics during the two-year period following the acquisition, is also measured at fair value on a recurring basis. The fair value was estimated based on the present value of the amount expected to be paid at the end of the measurement period. At September 30, 2023, the fair value of the contingent consideration was estimated to be $ 2.3 million and was included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. Earnout liabilities are classified within Level 3 in the fair value hierarchy because the methodology used to develop the estimated fair value includes significant unobservable inputs reflecting management’s own assumptions. The table below presents a reconciliation of earnout liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3): (in thousands) September 30, December 31, Balance at beginning of period $ 2,250 $ 7,500 Additions 7,800 1,000 Net change in fair value and other adjustments — 1,250 Payments — ( 7,500 ) Balance at end of period $ 10,050 $ 2,250 Non-recurring fair value measurements Certain assets and liabilities, including property, plant, and equipment, lease right-of-use assets, goodwill, and other intangible assets, are measured at fair value on a non-recurring basis. These assets are remeasured when the derived fair value is below the carrying value on the Company’s condensed consolidated balance sheet. For these assets, the Company does not periodically adjust carrying value to fair value except in the event of impairment. When impairment has occurred, the Company measures the required charges and adjusts the carrying value as discussed in Note 2. Summary of Significant Accounting Policies of the notes to the consolidated financial statements in the Company’s 2022 Form 10-K/A. The Company performed an interim goodwill impairment test during the third quarter of 2023 and concluded that the carrying value of its single reporting unit exceeded its fair value and recorded a $ 287.4 million non-cash goodwill impairment charge for the three months ended September 30, 2023. See Note 7. Goodwill and Intangible Assets . At September 30, 2023 and December 31, 2022 , assets and liabilities measured at fair value on a recurring basis were as follows: September 30, 2023 (in thousands) Total Level 1 Level 2 Level 3 Assets: Cash and cash equivalents: Money market funds $ 46,946 $ 46,946 $ — $ — Commercial paper (maturities less than 90 days) 6,222 — 6,222 — Short-term investments: U.S. Treasuries 96,471 — 96,471 — Agency bonds 1,107 — 1,107 — Corporate Bonds 2,280 — 2,280 Commercial paper 104,646 — 104,646 — Certificates of deposit 25,061 — 25,061 — Prepaid expenses and other current assets: Interest rate swap contracts 4,266 — 4,266 — Other assets: Interest rate swap contracts 1,600 — 1,600 — Liabilities: Accrued expenses and other current liabilities: Current portion of contingent consideration 2,250 — — 2,250 Other long-term liabilities Long-term portion of contingent consideration 7,800 — — 7,800 December 31, 2022 (in thousands) Total Level 1 Level 2 Level 3 Assets: Cash and cash equivalents: Money market funds $ 39,523 $ 39,523 $ — $ — Commercial paper (maturities less than 90 days) 2,276 — 2,276 — Certificates of deposit (maturities less than 90 days) 1,549 — 1,549 — Agency bonds (maturities less than 90 days) 768 — 768 — Short-term investments: U.S. Treasuries 59,723 — 59,723 — Agency bonds 6,452 — 6,452 — Commercial paper 95,737 — 95,737 — Certificates of deposit 23,027 — 23,027 — Prepaid expenses and other current assets: Interest rate swap contracts 3,716 — 3,716 — Other assets: Interest rate swap contracts 2,834 — 2,834 — Liabilities: Other long-term liabilities: Contingent consideration 2,250 — — 2,250 At September 30, 2023 and December 31, 2022 , except for the contingent consideration noted above, the estimated fair values of all of the Company’s financial assets and liabilities subject to the three-level fair value hierarchy approximated their carrying values due to their short-term maturities (less than 12 months).

Noncontrolling Interest

Noncontrolling Interest	9 Months Ended
	Sep. 30, 2023
Noncontrolling Interest [Abstract]
Noncontrolling Interest	12. Noncontrolling Interest Definitive Healthcare Corp. operates and controls all of the business and affairs of Definitive OpCo, and through Definitive OpCo and its subsidiaries, conducts its business. Accordingly, Definitive Healthcare Corp. consolidates the financial results of Definitive OpCo, and reports the noncontrolling interests of its consolidated subsidiaries on its condensed consolidated financial statements based on the LLC Units held by Continuing Pre-IPO LLC Members other than Definitive Healthcare Corp. Changes in Definitive Healthcare Corp.'s ownership interest in its consolidated subsidiaries are accounted for as equity transactions. As such, future redemptions or direct exchanges of LLC Units by such Continuing Pre-IPO LLC Members will result in a change in ownership and reduce or increase the amount recorded as noncontrolling interests and increase or decrease additional paid-in capital in the Company’s Condensed Consolidated Balance Sheets. During the nine months ended September 30, 2023, 10,547,065 LLC Units held by Continuing Pre-IPO LLC Members were exchanged for shares of Class A Common Stock of Definitive Healthcare Corp. pursuant to the terms of the Amended LLC Agreement. In addition, 904,919 restricted stock units vested and 308,295 shares were withheld to cover withholding tax obligations, resulting in the net issuance of 596,624 shares of Class A Common Stock of Definitive Healthcare Corp., for which LLC Units were issued on a one-for-one basis pursuant to the Definitive OpCo second amended and restated limited liability company agreement entered into in connection with the IPO. As of September 30, 2023 and December 31, 2022, Definitive Healthcare Corp. held ownership interests in Definitive OpCo of 74.8 % and 68.2 %, respectively, and noncontrolling interests of 25.2 % and 31.8 %, respectively .

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	9 Months Ended
	Sep. 30, 2023
Stockholders' Equity Note [Abstract]
Accumulated Other Comprehensive Income	13. Accumulated Other Comprehensive Income The following table summarize the changes in accumulated balances of other comprehensive income for the three and nine months ended September 30, 2023 and 2022, respectively. Three Months Ended September 30, 2023 Nine Months Ended September 30, 2023 (in thousands) Unrealized Gain (Loss) on Cash Flow Hedges Unrealized (Loss) Gain on Investments Foreign Currency Translation Adjustments Total Unrealized Gain (Loss) on Cash Flow Hedges Unrealized Loss on Investments Foreign Currency Translation Adjustments Total Beginning balance $ 4,158 $ ( 326 ) $ ( 580 ) $ 3,252 $ 4,307 $ ( 135 ) $ ( 504 ) $ 3,668 Other comprehensive income (loss) before reclassifications 505 148 ( 22 ) 631 1,710 ( 43 ) ( 98 ) 1,569 Amounts reclassified from AOCI ( 832 ) — — ( 832 ) ( 2,186 ) — — ( 2,186 ) Ending balance $ 3,831 $ ( 178 ) $ ( 602 ) $ 3,051 $ 3,831 $ ( 178 ) $ ( 602 ) $ 3,051 Three months ended September 30, 2022, as restated Nine months ended September 30, 2022, as restated (in thousands) Unrealized Gain (Loss) on Cash Flow Hedges Unrealized (Loss) Gain on Investments Foreign Currency Translation Adjustments Total Unrealized Gain on Cash Flow Hedges Unrealized Loss on Investments Foreign Currency Translation Adjustments Total Beginning balance $ 2,150 $ ( 290 ) $ ( 187 ) $ 1,673 $ — $ — $ 62 $ 62 Other comprehensive income (loss) before reclassifications 2,288 31 ( 34 ) 2,285 $ 4,162 $ ( 259 ) $ ( 283 ) 3,620 Amounts reclassified from AOCI ( 47 ) — — ( 47 ) 229 — — 229 Ending balance $ 4,391 $ ( 259 ) $ ( 221 ) $ 3,911 $ 4,391 $ ( 259 ) $ ( 221 ) $ 3,911

Equity-Based Compensation

Equity-Based Compensation	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Equity-Based Compensation	14. Equity-Based Compensation The Company recognizes equity-based compensation expense associated with awards granted under equity incentive plans. Equity-based compensation expense is allocated to all departments based on the recipients of the compensation. A summary of the expense by line item in the condensed consolidated statements of operations for the three and nine months ended September 30, 2023 and 2022, respectively, is provided in the following table. Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Cost of revenue $ 276 $ 236 $ 830 $ 698 Sales and marketing 2,728 2,260 8,297 11,062 Product development 3,236 2,171 9,566 5,301 General and administrative 5,754 4,466 16,792 7,949 Total compensation expense $ 11,994 $ 9,133 $ 35,485 $ 25,010

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	15. Income Taxes During the nine months ended September 30, 2023, management performed an assessment of the recoverability of deferred tax assets. Management determined, based on the accounting standards applicable to such assessment, that there was sufficient negative evidence as a result of the Company’s scheduled reversal of deferred tax liabilities and cumulative losses to conclude it was more likely than not that its deferred tax assets would not be realized and has recorded a valuation allowance against its deferred tax assets that are not more likely than not to be realized. In the event that management was to determine that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, an adjustment to the valuation allowance would be made which would reduce the provision for income taxes. As of September 30, 2023 and December 31, 2022 , the Company has recorded net deferred tax liabilities of $ 65.4 million and $ 75.6 million, respectively. The net deferred tax liability reflects a valuation allowance against deferred tax assets that are more likely than not to not be realized as well as reversing taxable temporary differences that will not provide a source of taxable income due to attribute limitation rules. The Company recognizes uncertain income tax positions when it is more-likely-than-not the position will be sustained upon examination. As of September 30, 2023 and December 31, 2022 , the Company has no t identified any uncertain tax positions and has not recognized any related reserves. The Company's effective tax rate was 6.6 % and 0.2 % , as restated, for the three months ended September 30, 2023 and 2022, respectively, and 6.7 % and 2.1 % , as restated, for the nine months ended September 30, 2023 and 2022 , respectively. The Company’s effective tax rate differs from the statutory tax rate of 21 % due to the valuation allowance recorded, foreign tax rates that differ from the U.S. statutory tax rate, and partnership income that is not taxed. As described above, the Company has a valuation allowance as it has not yet attained a sustained level of profitability and the objectively verifiable negative evidence outweighed the positive evidence. The income of the Company’s subsidiaries is generally subject to corporate-level taxation, and certain of these subsidiaries have a valuation allowance whereas others do not. The effective tax rates for each period generally arise from the tax provisions for Company subsidiaries without valuation allowances, and the impact of any revaluation of deferred taxes arising from changes in the states effective tax rates. Such revaluations are caused by changes in state apportionment factors arising from fluctuations in the mix of sales, property and payroll by state, certain state tax rate changes and certain state tax incentives. Tax Receivable Agreement Pursuant to the Company’s election under Section 754 of the Internal Revenue Code (the “Code”), the Company expects to obtain an increase in its share of the tax basis in the net assets of Definitive OpCo when LLC Interests are redeemed or exchanged by other members. The Company intends to treat any redemptions and exchanges of LLC Interest as direct purchases of LLC Interests for U.S. federal income tax purposes. These increases in tax basis may reduce the amounts that would otherwise be paid in the future to various tax authorities. They may also decrease gains (or increase losses) on future dispositions of certain capital assets to the extent tax basis is allocated to those capital assets. In connection with the IPO, the Company entered into a Tax Receivable Agreement (“TRA”) among Definitive Healthcare Corp., Definitive OpCo, and the TRA Parties and has recorded a liability under the TRA of $ 145.4 milli on and $ 155.1 million, as restated, as of September 30, 2023 and December 31, 2022, respectively. During the three and nine months ended September 30, 2023, the Company recognized a TRA remeasurement gain of $ 29.7 million and $ 25.0 million, respectively. During the three and nine months ended September 30, 2022 , the Company recognized a TRA remeasurement gain of $ 5.3 million, as restated, and $ 8.6 million, as restated, respectively. Gains in both periods were recognized within other income, net in the Company’s condensed consolidated statements of operations. Under the TRA, the Company generally will be required to pay to the TRA Parties 85 % of the amount of cash savings, if any, in U.S. federal, state, or local tax that the Company actually realizes directly or indirectly (or are deemed to realize in certain circumstances) as a result of (i) certain tax basis adjustments resulting from (a) acquisitions by the Company of LLC Units from pre-IPO holders in connection with the IPO, and (b) subsequent redemptions or exchanges of LLC Units by holders for Class A Common Stock or other consideration, (ii) certain tax attributes acquired by the Company from the Blocker Companies in the Reorganization Transactions, and (iii) certain payments made under the TRA. The Company expects to benefit from the remaining 15 % of any tax benefits that it may actually realize. To the extent that the Company is unable to timely make payments under the TRA for any reason, such payments generally will be deferred and will accrue interest until paid.

Loss Per Share

Loss Per Share	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Loss Per Share	16. Loss Per Share Basic net loss per share of Class A Common Stock is computed by dividing net income attributable to Definitive Healthcare Corp. by the weighted-average number of shares of Class A Common Stock outstanding during the period, excluding unvested equity awards and subsidiary member units not exchanged. Diluted earnings per share of Class A Common Stock is calculated by dividing net income attributable to Definitive Healthcare Corp., adjusted for the assumed exchange of all potentially dilutive securities by the weighted-average number of shares of Class A Common Stock outstanding. The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted net loss per share of Class A Common Stock for the three and nine months ended September 30, 2023 and 2022 . Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 (in thousands) (As Restated) (As Restated) Numerator: Net loss $ ( 248,688 ) $ ( 6,885 ) $ ( 276,265 ) $ ( 30,066 ) Less: Net loss attributable to noncontrolling interests ( 77,162 ) ( 3,865 ) ( 84,110 ) ( 12,979 ) Net loss attributable to Definitive Healthcare Corp. $ ( 171,526 ) $ ( 3,020 ) $ ( 192,155 ) ( 17,087 ) The following table sets forth the computation of basic and diluted net loss per share of Class A Common Stock for the three and nine months ended September 30, 2023 and 2022 (per share amounts unaudited). Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 (in thousands, except number of shares and per share amounts) (As Restated) (As Restated) Basic net loss per share attributable to common stockholders Numerator: Allocation of net loss attributable to Definitive Healthcare Corp. $ ( 171,526 ) $ ( 3,020 ) $ ( 192,155 ) $ ( 17,087 ) Denominator: Weighted average number of shares of Class A Common Stock outstanding 114,527,514 102,904,565 111,533,166 99,776,742 Net loss per share, basic and diluted $ ( 1.50 ) $ ( 0.03 ) $ ( 1.72 ) $ ( 0.17 ) Shares of the Company’s Class B Common Stock do not participate in the earnings or losses of Definitive Healthcare Corp. and are therefore not participating securities. As such, separate presentation of basic and diluted earnings per share of Class B Common Stock under the two-class method has not been presented. The following table presents potentially dilutive securities excluded from the computation of diluted net loss per share for the period presented because their effect would have been anti-dilutive: Nine Months Ended September 30, 2023 2022 Definitive OpCo LLC Units (vested and unvested) 39,781,946 50,566,898 Restricted Stock Units 6,847,050 3,411,944

Related Parties

Related Parties	9 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
Related Parties	17. Related Parties The Company has engaged in revenue transactions within the ordinary course of business with entities affiliated with its Sponsors and with members of the Company’s board of directors. During each of the three months ended September 30, 2023 and 2022 the Company recorded revenue from related parties of $ 0.3 million and $ 0.2 million, respectively. During each of the nine months ended September 30, 2023 and 2022, the Company recorded revenue from related parties of $ 1.1 million and $ 0.7 million, respectively. There were no receivables for related party revenue transactions at September 30, 2023. Receivables for related party revenue transactions amounted to $ 0.8 million at December 31, 2022 .

Summary of Significant Accounti

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and in conformity with rules applicable to quarterly financial information. Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative nongovernmental GAAP as found in the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”). The condensed consolidated financial statements as of September 30, 2023 and for the three and nine months ended September 30, 2023 and 2022 are unaudited and should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2022. All adjustments, consisting of normal recurring adjustments, except as otherwise noted, considered, in the opinion of management, necessary for a fair presentation of the unaudited interim condensed consolidated financial statements for these interim periods have been included. Refer to Note 2. Summary of Significant Accounting Policies in the notes to the consolidated financial statements in the 2022 Form 10-K/A for the Company’s significant accounting policies and estimates.
Use of Estimates in the Preparation of Financial Statements	Use of Estimates in the Preparation of Financial Statements The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of revenues and expenses during the reporting period. These estimates include, but are not limited to, revenue recognition, allowance for doubtful accounts, contingencies, valuations, useful lives of intangible assets acquired in business combinations, equity-based compensation, and income taxes. Actual results could differ from those estimates.
Adoption of Recently Issued Financial Accounting Standards	Adoption of Recently Issued Financial Accounting Standards In June 2016, the FASB issued ASU No. 2016-13— Financial Instruments – Credit Losses (Topic 326) – Measurement of Credit Losses on Financial Instruments . This standard is intended to improve financial reporting by requiring earlier recognition of credit losses on financing receivables and other financial assets in scope, such as trade receivables. The amendment is effective for fiscal years beginning after December 15, 2022. The Company adopted the update effective January 1, 2023 and the adoption of the standard did not have a material impact on the Company's condensed consolidated financial statements for the quarter ended September 30, 2023. Recently Issued Accounting Pronouncements Not Yet Adopted From time to time, new accounting pronouncements are issued by the FASB or other accounting standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed, we do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated statements or disclosures.
Restatement of Previously Issued Financial Statements	Restatement of Previously Issued Financial Statements The financial statements for the three and nine months ended September 30, 2022, have been restated to reflect the correction of misstatements related to the collection of sales taxes from sales of services to customers further described below (the “Misstatements”), along with other immaterial adjustments. The Company also restated all amounts within the notes to the financial statements. A description of adjustments and their impact on the previously issued financial statements are included below. In the first quarter of 2023, the Company began a review of its sales tax positions, and related accounting matters, with the assistance of outside consultants. As a result of the review, the Company determined during the second quarter of 2023 that sales in certain states were subject to sales tax and that the Company had not assessed such sales tax on sales of its services to customers. The Company determined that it did not accrue sales taxes and corrected these Misstatements by recording sales tax accruals through general and administrative expense as of the end of each affected period. These accrual amounts assume that (i) customers who have not yet provided certificates or other documentation of exemption from sales tax are taxable, (ii) maximum interest and penalty assessments may be imposed, and (iii) the Company will not receive waivers of interest and penalties or other benefits under agreements it may obtain with jurisdictions from its outreach with voluntarily disclosures. The Company expects to make adjustments to the sales tax liability in future periods based on the results of the voluntary disclosure agreements, including, but not limited to, classification of exempt sales based on customer exemption certificates, waivers of interest and penalties, or other benefits. The Misstatements that appeared in the previously issued financial statements were material, and the Company has also corrected other immaterial errors, which are further described below. As described in additional detail in the Explanatory Note in our 2022 Form 10-K/A, the Company restated its audited consolidated financial statements as of and for the years ended December 31, 2022, 2021 and 2020, as well as the unaudited condensed consolidated quarterly financial information for the quarterly periods in the fiscal years ended December 31, 2022, 2021, and 2020, to reflect the correction of the Misstatements and other immaterial adjustments, and to make corresponding disclosures. The Company also filed an Amendment No. 1 on Form 10-Q/A to amend the Quarterly Report on Form 10-Q for the three months ended March 31, 2023 with the SEC on August 14, 2023, to restate its unaudited condensed consolidated financial statements for the three months ended March 31, 2023 and 2022. A summary of the impacts of the Misstatements and other immaterial adjustments is as follows: Three Months Ended September 30, 2022 Nine Months Ended September 30, 2022 (in thousands) As previously reported As Restated As previously reported As Restated Net loss $ ( 6,354 ) $ ( 6,885 ) $ ( 28,990 ) $ ( 30,066 ) Net loss attributable to noncontrolling interests ( 3,665 ) ( 3,865 ) ( 12,527 ) ( 12,979 ) Net loss attributable to Definitive Healthcare Corp. ( 2,689 ) ( 3,020 ) ( 16,463 ) ( 17,087 ) As of September 30, 2022 (in thousands) As previously reported As Restated Total assets $ 2,119,773 $ 2,121,404 Total liabilities 642,251 648,311 Total equity 1,477,522 1,473,093 The categories of restatement adjustments and their impacts on previously reported financial statements are described below: a) Sales Tax and Related Misstatements – Sales tax on sales of services to customers who were subject to sales tax, inclusive of maximum penalties and interest, that was not previously accrued by the Company is corrected by an increase to accrued expenses and other current liabilities on the condensed consolidated balance sheets and an increase to general and administrative expenses on the condensed consolidated statements of operations. b) Related Impact on Tax Receivable Agreement ( “ TRA ” ) – Any impact on tax receivable gains and losses due to the corrections in (a) above is reflected as a change in the tax receivable agreement liability on the balance sheet and a change in other expense on the condensed consolidated statements of operations. c) Purchase Price Allocation Misstatement – In connection with the Company’s acquisition of Monocl Holding Company, the Company had previously failed to record a deferred tax liability related to identified intangible assets of Monocl Holding Company. Therefore, the Company corrected the opening purchase price of Monocl Holding Company to record an opening deferred tax liability with an offset to goodwill on the condensed consolidated balance sheets. The opening deferred tax liability subsequently resulted in an increase in benefit from income taxes on the consolidated statements of operations through the period ending March 31, 2022. d) Related Impact on Noncontrolling Interests – Any impact on noncontrolling interests resulting from the allocation of net loss due to the corrections in (a) and (c) above is reflected as (i) a change in the net loss attributable to noncontrolling interests on the condensed consolidated statements of operations, and (ii) a change in noncontrolling interests on the condensed consolidated balance sheets. The following table sets forth the corrections in each of the line items affected in the consolidated statements of operations for each respective period: (in thousands) Three Months Ended September 30, 2022 Nine Months Ended Increase in general and administrative expense (a) $ 631 $ 1,876 Increase in gain on remeasurement of TRA liability (other income) (b) 100 287 Increase in benefit from income taxes (c) — 513 Increase in net loss due to restatement items 531 1,076 Increase in net loss attributable to noncontrolling interests due to restatement items (d) 200 452 Increase in net loss attributable to Definitive Healthcare Corp. due to restatement items 331 624 See footnote descriptions above Three Months Ended Nine Months Ended (in thousands, except share amounts and per share data) As previously reported As Restated As previously reported As Restated Revenue $ 57,382 $ 57,382 $ 162,054 $ 162,054 Cost of revenue: Cost of revenue exclusive of amortization 6,569 6,569 18,717 18,717 Amortization 3,155 3,155 14,113 14,113 Gross profit 47,658 47,658 129,224 129,224 Operating expenses: Sales and marketing 21,184 21,184 66,062 66,062 Product development 9,205 9,205 24,761 24,761 General and administrative 13,718 14,349 33,564 35,440 Depreciation and amortization 10,037 10,037 30,105 30,105 Transaction, integration, and restructuring expenses 2,945 2,945 6,362 6,362 Total operating expenses 57,089 57,720 160,854 162,730 Loss from operations ( 9,431 ) ( 10,062 ) ( 31,630 ) ( 33,506 ) Other income (expense), net: Interest income 608 608 858 858 Interest expense ( 3,074 ) ( 3,074 ) ( 7,788 ) ( 7,788 ) Other expense, net 5,528 5,628 9,429 9,716 Total other expense, net 3,062 3,162 2,499 2,786 Loss before income taxes ( 6,369 ) ( 6,900 ) ( 29,131 ) ( 30,720 ) Benefit from income taxes 15 15 141 654 Net loss ( 6,354 ) ( 6,885 ) ( 28,990 ) ( 30,066 ) Less: Net loss attributable to noncontrolling interests ( 3,665 ) ( 3,865 ) ( 12,527 ) ( 12,979 ) Net loss attributable to Definitive Healthcare Corp. $ ( 2,689 ) $ ( 3,020 ) $ ( 16,463 ) $ ( 17,087 ) Net loss per share of Class A Common Stock: Basic and diluted $ ( 0.03 ) $ ( 0.03 ) $ ( 0.16 ) $ ( 0.17 ) Weighted average Common Stock outstanding: Basic and diluted (1) 102,904,565 102,904,565 99,776,742 99,776,742 The following table sets forth the corrections in each of the line items affected in the condensed consolidated balance sheets for September 30, 2022: (in thousands) As previously reported Restatement Adjustments As Restated Goodwill 1,322,959 1,631 1,324,590 Total assets 2,119,773 1,631 2,121,404 Accrued expenses and other current liabilities 18,885 7,203 26,088 Total current liabilities 121,552 7,203 128,755 Tax receivable agreements liability, net of current portion 157,175 ( 1,143 ) 156,032 Total liabilities 642,251 6,060 648,311 Additional paid-in capital 962,874 ( 1,873 ) 961,001 Accumulated deficit ( 34,140 ) ( 787 ) ( 34,927 ) Noncontrolling interests 544,772 ( 1,769 ) 543,003 Total equity 1,477,522 ( 4,429 ) 1,473,093 Total liabilities and equity 2,119,773 1,631 2,121,404 The following table sets forth the corrections in each of the line items affected in the condensed consolidated statements of changes in total equity for September 30, 2022: Additional Paid-In Accumulated Noncontrolling Total (in thousands) Capital Deficit Interests Equity As reported $ 962,874 $ ( 34,140 ) $ 544,772 $ 1,477,522 Adjustment due to cumulative error correction ( 1,873 ) ( 787 ) ( 1,769 ) ( 4,429 ) As restated $ 961,001 $ ( 34,927 ) $ 543,003 $ 1,473,093 The Company did not present tables for quarterly adjustments within the consolidated statements of cash flows since all of the foregoing adjustments only affected financial statement line items within cash flows from operating activities. The adjustments did not affect total cash flows from operating activities, financing activities, or investing activities for any period presented.

Organization and Basis of Pre_2

Organization and Basis of Presentation (Tables)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Summary of Effect of Restatement Item	A summary of the impacts of the Misstatements and other immaterial adjustments is as follows: Three Months Ended September 30, 2022 Nine Months Ended September 30, 2022 (in thousands) As previously reported As Restated As previously reported As Restated Net loss $ ( 6,354 ) $ ( 6,885 ) $ ( 28,990 ) $ ( 30,066 ) Net loss attributable to noncontrolling interests ( 3,665 ) ( 3,865 ) ( 12,527 ) ( 12,979 ) Net loss attributable to Definitive Healthcare Corp. ( 2,689 ) ( 3,020 ) ( 16,463 ) ( 17,087 ) As of September 30, 2022 (in thousands) As previously reported As Restated Total assets $ 2,119,773 $ 2,121,404 Total liabilities 642,251 648,311 Total equity 1,477,522 1,473,093
Schedule of Error Corrections and Prior Period Adjustments	The following table sets forth the corrections in each of the line items affected in the consolidated statements of operations for each respective period: (in thousands) Three Months Ended September 30, 2022 Nine Months Ended Increase in general and administrative expense (a) $ 631 $ 1,876 Increase in gain on remeasurement of TRA liability (other income) (b) 100 287 Increase in benefit from income taxes (c) — 513 Increase in net loss due to restatement items 531 1,076 Increase in net loss attributable to noncontrolling interests due to restatement items (d) 200 452 Increase in net loss attributable to Definitive Healthcare Corp. due to restatement items 331 624 See footnote descriptions above Three Months Ended Nine Months Ended (in thousands, except share amounts and per share data) As previously reported As Restated As previously reported As Restated Revenue $ 57,382 $ 57,382 $ 162,054 $ 162,054 Cost of revenue: Cost of revenue exclusive of amortization 6,569 6,569 18,717 18,717 Amortization 3,155 3,155 14,113 14,113 Gross profit 47,658 47,658 129,224 129,224 Operating expenses: Sales and marketing 21,184 21,184 66,062 66,062 Product development 9,205 9,205 24,761 24,761 General and administrative 13,718 14,349 33,564 35,440 Depreciation and amortization 10,037 10,037 30,105 30,105 Transaction, integration, and restructuring expenses 2,945 2,945 6,362 6,362 Total operating expenses 57,089 57,720 160,854 162,730 Loss from operations ( 9,431 ) ( 10,062 ) ( 31,630 ) ( 33,506 ) Other income (expense), net: Interest income 608 608 858 858 Interest expense ( 3,074 ) ( 3,074 ) ( 7,788 ) ( 7,788 ) Other expense, net 5,528 5,628 9,429 9,716 Total other expense, net 3,062 3,162 2,499 2,786 Loss before income taxes ( 6,369 ) ( 6,900 ) ( 29,131 ) ( 30,720 ) Benefit from income taxes 15 15 141 654 Net loss ( 6,354 ) ( 6,885 ) ( 28,990 ) ( 30,066 ) Less: Net loss attributable to noncontrolling interests ( 3,665 ) ( 3,865 ) ( 12,527 ) ( 12,979 ) Net loss attributable to Definitive Healthcare Corp. $ ( 2,689 ) $ ( 3,020 ) $ ( 16,463 ) $ ( 17,087 ) Net loss per share of Class A Common Stock: Basic and diluted $ ( 0.03 ) $ ( 0.03 ) $ ( 0.16 ) $ ( 0.17 ) Weighted average Common Stock outstanding: Basic and diluted (1) 102,904,565 102,904,565 99,776,742 99,776,742 The following table sets forth the corrections in each of the line items affected in the condensed consolidated balance sheets for September 30, 2022: (in thousands) As previously reported Restatement Adjustments As Restated Goodwill 1,322,959 1,631 1,324,590 Total assets 2,119,773 1,631 2,121,404 Accrued expenses and other current liabilities 18,885 7,203 26,088 Total current liabilities 121,552 7,203 128,755 Tax receivable agreements liability, net of current portion 157,175 ( 1,143 ) 156,032 Total liabilities 642,251 6,060 648,311 Additional paid-in capital 962,874 ( 1,873 ) 961,001 Accumulated deficit ( 34,140 ) ( 787 ) ( 34,927 ) Noncontrolling interests 544,772 ( 1,769 ) 543,003 Total equity 1,477,522 ( 4,429 ) 1,473,093 Total liabilities and equity 2,119,773 1,631 2,121,404 The following table sets forth the corrections in each of the line items affected in the condensed consolidated statements of changes in total equity for September 30, 2022: Additional Paid-In Accumulated Noncontrolling Total (in thousands) Capital Deficit Interests Equity As reported $ 962,874 $ ( 34,140 ) $ 544,772 $ 1,477,522 Adjustment due to cumulative error correction ( 1,873 ) ( 787 ) ( 1,769 ) ( 4,429 ) As restated $ 961,001 $ ( 34,927 ) $ 543,003 $ 1,473,093

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2023
Populi Inc. [Member]
Business Acquisition [Line Items]
Summary of Transaction Transferred	The consideration transferred for the transaction is summarized as follows: (in thousands) Cash consideration paid at closing $ 46,446 Working capital adjustment ( 164 ) Contingent consideration 7,800 Purchase price $ 54,082
Summary of Allocation of Purchase Price to the Fair Value of Assets Acquired	Acquisition-date fair values of assets and liabilities pertaining to this business combination have been allocated as follows: (in thousands) Purchase price allocation: Preliminary Cash $ 1,423 Accounts receivable 2,662 Prepaid expenses and other current assets 153 Property and equipment 42 Intangible assets 22,830 Accounts payable and accrued expenses ( 3,316 ) Deferred revenue ( 4,010 ) Other liabilities ( 2,354 ) Total assets acquired and liabilities assumed 17,430 Goodwill 36,652 Purchase price $ 54,082
Schedule of Business Acquisition, Pro Forma Information	Unaudited Pro Forma Supplementary Data as if the transaction had occurred on January 1, 2022: Nine Months Ended September 30, 2023 2022 (in thousands) Revenue $ 189,697 $ 166,204 Net loss ( 280,870 ) ( 36,423 )
Analytical Wizards [Member]
Business Acquisition [Line Items]
Summary of Transaction Transferred	The consideration transferred for the transaction is summarized as follows: (in thousands) Initial cash investment in December 2021 $ 40,000 Cash consideration paid at closing 58,645 Working capital adjustment ( 202 ) Contingent consideration 1,000 Purchase price $ 99,443
Summary of Allocation of Purchase Price to the Fair Value of Assets Acquired	The Company finalized the purchase price allocations of the AW acquisition during the first quarter of 2023. Acquisition-date fair values of assets and liabilities pertaining to this business combination have been allocated as follows: (in thousands) Purchase price allocation: Preliminary, as originally reported Measurement period adjustments As adjusted Cash $ 2,146 $ — $ 2,146 Accounts receivable 3,575 ( 50 ) 3,525 Prepaid expenses and other current assets 506 341 847 Property and equipment 134 — 134 Intangible assets 46,000 — 46,000 Right-of-use asset, operating leases 832 — 832 Other assets — 703 703 Accounts payable and accrued expenses ( 485 ) ( 543 ) ( 1,028 ) Deferred revenue ( 3,691 ) 326 ( 3,365 ) Right-of-use liability, operating leases ( 832 ) — ( 832 ) Deferred taxes ( 10,345 ) 67 ( 10,278 ) Other liabilities ( 267 ) ( 633 ) ( 900 ) Total assets acquired and liabilities assumed 37,573 211 37,784 Goodwill 62,072 ( 413 ) 61,659 Purchase price $ 99,645 $ ( 202 ) $ 99,443
Schedule of Business Acquisition, Pro Forma Information	Unaudited Pro Forma Supplementary Data: Nine Months Ended September 30, 2022 (in thousands) (As Restated) Revenue $ 163,531 Net loss ( 29,566 )

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue	The following table represents a disaggregation of revenue from arrangements with customers for the three and nine months ended September 30, 2023 and 2022, respectively: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Subscription services $ 62,568 $ 56,156 $ 180,358 $ 159,136 Professional services 2,757 1,226 5,125 2,918 Total revenue $ 65,325 $ 57,382 $ 185,483 $ 162,054
Summary of Receivables, Deferred Contract Costs and Contract Liabilities from Contract with Customers	The opening and closing balances of the Company’s receivables, deferred contract costs and contract liabilities from contracts with customers are as follows: (in thousands) September 30, December 31, Accounts receivable, net $ 41,308 $ 58,799 Deferred contract costs, current portion 12,396 10,387 Deferred contract costs, long-term 16,132 14,596 Deferred revenues 89,781 99,928 Deferred Contract Costs A summary of the activity impacting the deferred contract costs for the nine months ended September 30, 2023 and the year ended December 31, 2022 is presented below: (in thousands) Nine Months Ended September 30, 2023 Twelve Months Ended December 31, 2022 Balance at beginning of period $ 24,983 $ 18,547 Costs amortized ( 9,475 ) ( 8,816 ) Additional amounts deferred 13,020 15,252 Balance at end of period 28,528 24,983 Classified as: Current 12,396 10,387 Non-current 16,132 14,596 Total deferred contract costs (deferred commissions) $ 28,528 $ 24,983
Summary of Deferred Revenue Balances	A summary of the activity impacting deferred revenue balances during the nine months ended September 30, 2023 and for the year ended December 31, 2022 is presented below: (in thousands) Nine Months Ended September 30, 2023 Twelve Months Ended December 31, 2022 Balance at beginning of period $ 99,928 $ 84,023 Revenue recognized ( 185,483 ) ( 222,653 ) Additional amounts deferred 175,336 238,558 Balance at end of period $ 89,781 $ 99,928
Summary of Remaining Performance Obligation	The remaining performance obligations consisted of the following: (in thousands) September 30, December 31, Current $ 170,782 $ 183,527 Non-current 82,462 93,464 Total $ 253,244 $ 276,991

Short-term Investments (Tables)

Short-term Investments (Tables)	9 Months Ended
	Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Schedule of short-term investments	Short-term investments classified as available-for-sale consisted of the following: September 30, 2023 (in thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Short-term investments: US Treasuries $ 96,668 $ — $ ( 197 ) $ 96,471 Agency bonds 1,107 — — 1,107 Corporate Bonds 2,280 — — 2,280 Commercial paper 104,719 1 ( 74 ) 104,646 Certificates of deposit 25,072 3 ( 14 ) 25,061 Total short-term investments $ 229,846 $ 4 $ ( 285 ) $ 229,565 December 31, 2022 (in thousands) Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Short-term investments: US Treasuries $ 59,849 $ 3 $ ( 129 ) $ 59,723 Agency bonds 6,450 4 ( 2 ) 6,452 Commercial paper 95,831 29 ( 123 ) 95,737 Certificates of deposit 23,034 17 ( 24 ) 23,027 Total short-term investments $ 185,164 $ 53 $ ( 278 ) $ 184,939

Accounts Receivable (Tables)

Accounts Receivable (Tables)	9 Months Ended
	Sep. 30, 2023
Receivables [Abstract]
Schedule of Accounts Receivable	Accounts receivable consisted of the following: (in thousands) September 30, December 31, Accounts receivable $ 42,037 $ 59,780 Unbilled receivable 959 881 42,996 60,661 Less: allowance for doubtful accounts ( 1,688 ) ( 1,862 ) Accounts receivable, net $ 41,308 $ 58,799

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consisted of the following: (in thousands) September 30, December 31, Computers and software $ 7,003 $ 5,924 Furniture and equipment 1,420 1,204 Leasehold improvements 2,283 2,134 10,706 9,262 Less: accumulated depreciation and amortization ( 6,078 ) ( 4,798 ) Property and equipment, net $ 4,628 $ 4,464

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets and Goodwill	The carrying amounts of goodwill and intangible assets, as of September 30, 2023 and December 31, 2022, consisted of the following: September 30, 2023 (in thousands) Gross Accumulated Net Carrying Finite-lived intangible assets: Customer relationships $ 410,710 $ ( 154,789 ) $ 255,921 Developed technologies 78,324 ( 31,627 ) 46,697 Tradenames 36,021 ( 8,775 ) 27,246 Database 50,204 ( 44,041 ) 6,163 Total finite-lived intangible assets 575,259 ( 239,232 ) 336,027 Goodwill 1,073,986 — 1,073,986 Total goodwill and intangible assets $ 1,649,245 $ ( 239,232 ) $ 1,410,013 December 31, 2022 Gross Accumulated Net Carrying (in thousands) (As Restated) Finite-lived intangible assets: Customer relationships $ 409,430 $ ( 128,745 ) $ 280,685 Developed technologies 56,965 ( 25,514 ) 31,451 Tradenames 35,914 ( 7,150 ) 28,764 Database 50,215 ( 40,393 ) 9,822 Total finite-lived intangible assets 552,524 ( 201,802 ) 350,722 Goodwill 1,324,733 — 1,324,733 Total goodwill and intangible assets $ 1,877,257 $ ( 201,802 ) $ 1,675,455
Schedule of Future Amortization Expense	Estimated total intangible amortization expense during the next five years and thereafter is as follows: (in thousands) 2023, excluding the nine months ended September 30, 2023 $ 12,479 2024 48,455 2025 45,945 2026 39,305 2027 33,357 Thereafter 156,486 Total $ 336,027
Schedule of Goodwill	As of September 30, 2023 and December 31, 2022, goodwill consisted of the following: (in thousands) Nine Months Ended Twelve Months Ended Goodwill - beginning of period $ 1,324,733 $ 1,263,075 Goodwill acquired during period 36,653 61,658 Goodwill impairment loss ( 287,400 ) — Goodwill - end of period $ 1,073,986 $ 1,324,733

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2023
Accounts Payable and Accrued Liabilities, Current [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following: September 30, December 31, (in thousands) (As Restated) Payroll and payroll-related $ 10,503 $ 11,961 Tax receivable agreement, current portion 6,673 — Contingent consideration, current 2,250 — Sales, franchise, and other taxes 11,352 11,738 Other 5,208 3,156 Accrued expenses and other current liabilities $ 35,986 $ 26,855

Long-Term Debt (Tables)

Long-Term Debt (Tables)	9 Months Ended
	Sep. 30, 2023
Long-Term Debt, Unclassified [Abstract]
Schedule of Long-term Debt	Long-term debt consisted of the following as of September 30, 2023 and December 31, 2022, respectively: September 30, 2023 (in thousands) Principal Unamortized debt Total debt, 2021 Term Loan $ 261,250 $ ( 1,634 ) $ 259,616 Less: current portion of long-term debt 13,750 Long-term debt $ 245,866 December 31, 2022 (in thousands) Principal Unamortized debt Total debt, 2021 Term Loan $ 266,406 $ ( 2,047 ) $ 264,359 Less: current portion of long-term debt 8,594 Long-term debt $ 255,765

Derivative Instruments and He_2

Derivative Instruments and Hedging Activities (Tables)	9 Months Ended
	Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of Fair Values of the Interest Rate Swap	The fair values of the interest rate swaps and their respective locations in our condensed consolidated balance sheets at September 30, 2023 and December 31, 2022 were as follows: (in thousands) Description Balance Sheet Location September 30, 2023 December 31, 2022 Short-term derivative asset Prepaid expenses and other current assets $ 4,266 $ 3,716 Long-term derivative asset Other assets 1,600 2,834

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2023
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]
Schedule of Reconciliation of Earnout Liabilities Measured at Fair Value on a Recurring Basis Unobservable Inputs	The table below presents a reconciliation of earnout liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3): (in thousands) September 30, December 31, Balance at beginning of period $ 2,250 $ 7,500 Additions 7,800 1,000 Net change in fair value and other adjustments — 1,250 Payments — ( 7,500 ) Balance at end of period $ 10,050 $ 2,250
Schedule of Fair Value of Assets and Liabilities Measured at Fair Value on Recurring Basis	At September 30, 2023 and December 31, 2022 , assets and liabilities measured at fair value on a recurring basis were as follows:

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Sep. 30, 2023
Stockholders' Equity Note [Abstract]
Summary of Changes in Accumulated Balances in Other Comprehensive Income	The following table summarize the changes in accumulated balances of other comprehensive income for the three and nine months ended September 30, 2023 and 2022, respectively. Three Months Ended September 30, 2023 Nine Months Ended September 30, 2023 (in thousands) Unrealized Gain (Loss) on Cash Flow Hedges Unrealized (Loss) Gain on Investments Foreign Currency Translation Adjustments Total Unrealized Gain (Loss) on Cash Flow Hedges Unrealized Loss on Investments Foreign Currency Translation Adjustments Total Beginning balance $ 4,158 $ ( 326 ) $ ( 580 ) $ 3,252 $ 4,307 $ ( 135 ) $ ( 504 ) $ 3,668 Other comprehensive income (loss) before reclassifications 505 148 ( 22 ) 631 1,710 ( 43 ) ( 98 ) 1,569 Amounts reclassified from AOCI ( 832 ) — — ( 832 ) ( 2,186 ) — — ( 2,186 ) Ending balance $ 3,831 $ ( 178 ) $ ( 602 ) $ 3,051 $ 3,831 $ ( 178 ) $ ( 602 ) $ 3,051 Three months ended September 30, 2022, as restated Nine months ended September 30, 2022, as restated (in thousands) Unrealized Gain (Loss) on Cash Flow Hedges Unrealized (Loss) Gain on Investments Foreign Currency Translation Adjustments Total Unrealized Gain on Cash Flow Hedges Unrealized Loss on Investments Foreign Currency Translation Adjustments Total Beginning balance $ 2,150 $ ( 290 ) $ ( 187 ) $ 1,673 $ — $ — $ 62 $ 62 Other comprehensive income (loss) before reclassifications 2,288 31 ( 34 ) 2,285 $ 4,162 $ ( 259 ) $ ( 283 ) 3,620 Amounts reclassified from AOCI ( 47 ) — — ( 47 ) 229 — — 229 Ending balance $ 4,391 $ ( 259 ) $ ( 221 ) $ 3,911 $ 4,391 $ ( 259 ) $ ( 221 ) $ 3,911

Equity-Based Compensation (Tabl

Equity-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Summary of Equity Based Compensation Expense Recognized	A summary of the expense by line item in the condensed consolidated statements of operations for the three and nine months ended September 30, 2023 and 2022, respectively, is provided in the following table. Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Cost of revenue $ 276 $ 236 $ 830 $ 698 Sales and marketing 2,728 2,260 8,297 11,062 Product development 3,236 2,171 9,566 5,301 General and administrative 5,754 4,466 16,792 7,949 Total compensation expense $ 11,994 $ 9,133 $ 35,485 $ 25,010

Loss Per Share (Tables)

Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Schedule of Net Loss Per Share, Basic and Diluted	The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted net loss per share of Class A Common Stock for the three and nine months ended September 30, 2023 and 2022 . Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 (in thousands) (As Restated) (As Restated) Numerator: Net loss $ ( 248,688 ) $ ( 6,885 ) $ ( 276,265 ) $ ( 30,066 ) Less: Net loss attributable to noncontrolling interests ( 77,162 ) ( 3,865 ) ( 84,110 ) ( 12,979 ) Net loss attributable to Definitive Healthcare Corp. $ ( 171,526 ) $ ( 3,020 ) $ ( 192,155 ) ( 17,087 ) The following table sets forth the computation of basic and diluted net loss per share of Class A Common Stock for the three and nine months ended September 30, 2023 and 2022 (per share amounts unaudited). Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 (in thousands, except number of shares and per share amounts) (As Restated) (As Restated) Basic net loss per share attributable to common stockholders Numerator: Allocation of net loss attributable to Definitive Healthcare Corp. $ ( 171,526 ) $ ( 3,020 ) $ ( 192,155 ) $ ( 17,087 ) Denominator: Weighted average number of shares of Class A Common Stock outstanding 114,527,514 102,904,565 111,533,166 99,776,742 Net loss per share, basic and diluted $ ( 1.50 ) $ ( 0.03 ) $ ( 1.72 ) $ ( 0.17 )
Schedule of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share	The following table presents potentially dilutive securities excluded from the computation of diluted net loss per share for the period presented because their effect would have been anti-dilutive: Nine Months Ended September 30, 2023 2022 Definitive OpCo LLC Units (vested and unvested) 39,781,946 50,566,898 Restricted Stock Units 6,847,050 3,411,944

Organization and Basis of Pre_3

Organization and Basis of Presentation - Additional Information (Details)	9 Months Ended
	Sep. 30, 2023
Entity Incorporation, Date of Incorporation	May 05, 2021

Organization and Basis of Pre_4

Organization and Basis of Presentation - Summary of Effect of Restatement Item (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Net loss		$ (6,885)		$ (30,066)
Net loss attributable to noncontrolling interests	$ (77,162)	(3,865)	$ (84,110)	(12,979)
Net loss attributable to Definitive Healthcare Corp.	(171,526)	(3,020)	(192,155)	(17,087)
Total assets	1,819,534	2,121,404	1,819,534	2,121,404	$ 2,122,624
Total liabilities	616,084	648,311	616,084	648,311	640,679
Total equity	$ 1,203,450	1,473,093	$ 1,203,450	1,473,093	$ 1,481,945
Previously Reported [Member]
Net loss		(6,354)		(28,990)
Net loss attributable to noncontrolling interests		(3,665)		(12,527)
Net loss attributable to Definitive Healthcare Corp.		(2,689)		(16,463)
Total assets		2,119,773		2,119,773
Total liabilities		642,251		642,251
Total equity		$ 1,477,522		$ 1,477,522

Organization and Basis of Pre_5

Organization and Basis of Presentation - Schedule of Corrections in the Consolidated Statements of Operations (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue	$ 65,325			$ 57,382			$ 185,483	$ 162,054
Cost of revenue:
Cost of revenue exclusive of amortization	8,663			6,569			25,293	18,717
Amortization	3,232			3,155			9,676	14,113
Gross profit	53,430			47,658			150,514	129,224
Operating expenses:
Sales and marketing	22,804			21,184			70,929	66,062
Product development	10,759			9,205			30,872	24,761
General and administrative	14,545			14,349			42,294	35,440
Depreciation and amortization	9,795			10,037			29,073	30,105
Transaction, integration and restructuring expenses	3,505			2,945			9,666	6,362
Total operating expenses	348,808			57,720			470,234	162,730
Loss from operations	(295,378)			(10,062)			(319,720)	(33,506)
Other income (expense), net:
Interest income	3,464			608			9,870	858
Interest expense	(3,897)			(3,074)			(11,304)	(7,788)
Other income, net	29,589			5,628			25,161	9,716
Total other income, net	29,156			3,162			23,727	2,786
Net loss before income taxes	(266,222)			(6,900)			(295,993)	(30,720)
Benefit from income taxes	17,534			15			19,728	654
Net loss	(248,688)	$ (11,605)	$ (15,972)	(6,885)	$ (10,142)	$ (13,039)	(276,265)	(30,066)
Less: Net loss attributable to noncontrolling interests	(77,162)			(3,865)			(84,110)	(12,979)
Net loss attributable to Definitive Healthcare Corp.	$ (171,526)			$ (3,020)			$ (192,155)	$ (17,087)
Net loss per share of Class A common stock:
Basic	$ (1.5)			$ (0.03)			$ (1.72)	$ (0.17)
Diluted	$ (1.5)			$ (0.03)			$ (1.72)	$ (0.17)
Weighted average Class A Common Stock outstanding:
Basic	114,527,514			102,904,565			111,533,166	99,776,742
Diluted	114,527,514			102,904,565			111,533,166	99,776,742
Restatement Adjustment [Member]
Operating expenses:
General and administrative				$ 631				$ 1,876
Other income (expense), net:
Total other income, net				100				287
Benefit from income taxes				0				513
Net loss				531				1,076
Less: Net loss attributable to noncontrolling interests				200				452
Net loss attributable to Definitive Healthcare Corp.				331				624
Previously Reported [Member]
Revenue				57,382				162,054
Cost of revenue:
Cost of revenue exclusive of amortization				6,569				18,717
Amortization				3,155				14,113
Gross profit				47,658				129,224
Operating expenses:
Sales and marketing				21,184				66,062
Product development				9,205				24,761
General and administrative				13,718				33,564
Depreciation and amortization				10,037				30,105
Transaction, integration and restructuring expenses				2,945				6,362
Total operating expenses				57,089				160,854
Loss from operations				(9,431)				(31,630)
Other income (expense), net:
Interest income				608				858
Interest expense				(3,074)				(7,788)
Other income, net				5,528				9,429
Total other income, net				3,062				2,499
Net loss before income taxes				(6,369)				(29,131)
Benefit from income taxes				15				141
Net loss				(6,354)				(28,990)
Less: Net loss attributable to noncontrolling interests				(3,665)				(12,527)
Net loss attributable to Definitive Healthcare Corp.				$ (2,689)				$ (16,463)
Net loss per share of Class A common stock:
Basic				$ (0.03)				$ (0.16)
Diluted				$ (0.03)				$ (0.16)
Weighted average Class A Common Stock outstanding:
Basic				102,904,565				99,776,742
Diluted				102,904,565				99,776,742

Organization and Basis of Pre_6

Organization and Basis of Presentation - Schedule of Corrections in the Consolidated Balance Sheets (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2021
Property and equipment, net	$ 4,628	$ 4,464
Operating lease right-of-use assets, net	9,951	9,681
Intangible assets, net	336,027	350,722
Goodwill	1,073,986	1,324,733	$ 1,324,590	$ 1,263,075
Total assets	1,819,534	2,122,624	2,121,404
Accrued Expenses And Other Current Liabilities	35,986	26,855	26,088
Total current liabilities	147,142	140,610	128,755
Tax receivable agreements liability, net of current portion	138,736	155,111	156,032
Total liabilities	616,084	640,679	648,311
Additional paid-in capital	1,077,332	970,207	961,001
Accumulated other comprehensive income	3,051	3,668
Accumulated deficit	(217,217)	(25,062)	(34,927)
Noncontrolling interests	340,168	533,027	543,003
Total equity	1,203,450	1,481,945	1,473,093
Total liabilities and equity	$ 1,819,534	$ 2,122,624	2,121,404
Previously Reported [Member]
Goodwill			1,322,959
Total assets			2,119,773
Accrued Expenses And Other Current Liabilities			18,885
Total current liabilities			121,552
Tax receivable agreements liability, net of current portion			157,175
Total liabilities			642,251
Additional paid-in capital			962,874
Accumulated deficit			(34,140)
Noncontrolling interests			544,772
Total equity			1,477,522
Total liabilities and equity			2,119,773
Restatement Adjustment [Member]
Goodwill			1,631
Total assets			1,631
Accrued Expenses And Other Current Liabilities			7,203
Total current liabilities			7,203
Tax receivable agreements liability, net of current portion			(1,143)
Total liabilities			6,060
Additional paid-in capital			(1,873)
Accumulated deficit			(787)
Noncontrolling interests			(1,769)
Total equity			(4,429)
Total liabilities and equity			$ 1,631

Organization and Basis of Pre_7

Organization and Basis of Presentation - Schedule of Corrections in the Condensed Consolidated Statements of Changes in Total Equity (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022
Beginning Balance	$ 1,455,459	$ 1,463,858	$ 1,481,945	$ 1,473,093	$ 1,484,438	$ 1,493,861	$ 1,499,836
Ending Balance	1,203,450	1,455,459	1,463,858	1,481,945	1,473,093	1,484,438	1,493,861
Additional Paid-in Capital [Member]
Beginning Balance	1,050,714	1,018,692	970,207	961,001	928,047	897,744	888,992
Ending Balance	1,077,332	1,050,714	1,018,692	970,207	961,001	928,047	897,744
Accumulated Other Comprehensive Income
Beginning Balance	3,252	2,793	3,668	3,911	1,673	918	62
Ending Balance	3,051	3,252	2,793	3,668	3,911	1,673	918
Accumulated Deficit [Member]
Beginning Balance	(45,691)	(37,125)	(25,062)	(34,927)	(31,907)	(26,421)	(17,840)
Ending Balance	(217,217)	(45,691)	(37,125)	(25,062)	(34,927)	(31,907)	(26,421)
Noncontrolling Interest [Member]
Beginning Balance	447,071	479,388	533,027	543,003	586,525	621,522	628,525
Ending Balance	$ 340,168	$ 447,071	$ 479,388	533,027	543,003	$ 586,525	$ 621,522
As Reported [Member]
Beginning Balance				1,477,522
Ending Balance					1,477,522
As Reported [Member] | Additional Paid-in Capital [Member]
Beginning Balance				962,874
Ending Balance					962,874
As Reported [Member] | Accumulated Deficit [Member]
Beginning Balance				(34,140)
Ending Balance					(34,140)
As Reported [Member] | Noncontrolling Interest [Member]
Beginning Balance				544,772
Ending Balance					544,772
Error Correction [Member]
Beginning Balance				(4,429)
Ending Balance					(4,429)
Error Correction [Member] | Additional Paid-in Capital [Member]
Beginning Balance				(1,873)
Ending Balance					(1,873)
Error Correction [Member] | Accumulated Deficit [Member]
Beginning Balance				(787)
Ending Balance					(787)
Error Correction [Member] | Noncontrolling Interest [Member]
Beginning Balance				$ (1,769)
Ending Balance					$ (1,769)

Acquisition - Additional Inform

Acquisition - Additional Information (Detail)					1 Months Ended	9 Months Ended	12 Months Ended
	Jul. 21, 2023 USD ($)	Jul. 17, 2023	Feb. 18, 2022 USD ($)	Dec. 22, 2021 USD ($)	Feb. 28, 2022 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)
Business Acquisition [Line Items]
Investment				$ 40,000,000
Purchase option ownership percentage				65%
Purchase of Ownership percentage					0.65
Cash consideration paid at closing	$ 46,400,000		$ 58,600,000
Cash consideration paid to Populi, Inc.	46,400,000		58,600,000
Working capital adjustments	200,000		200,000
Contingent consideration	28,000,000		5,000,000
Initial value of contingent consideration							$ 1,000,000
Fair value of the contingent consideration	7,800,000				$ 1,000,000
Initial cash investment in December 2021			40,000,000
Escrow deposit			10,000,000
Purchase price consideration					65,000,000
Business combination, Contingent consideration, Liability						$ 7,800,000
Software Development [Member]
Business Acquisition [Line Items]
Other assets	21,400,000				6,100,000
Populi Inc. [Member]
Business Acquisition [Line Items]
Cash consideration paid at closing	4,800,000					46,446,000
Cash consideration paid to Populi, Inc.	4,800,000					46,446,000
Purchase price	54,100,000					54,082,000
Working capital adjustments						(164,000)
Contingent consideration						7,800,000
Fair value of the contingent consideration	7,800,000
Transaction costs paid from proceeds						4,400,000
Populi Inc. [Member] | Software Development [Member]
Business Acquisition [Line Items]
Other assets	21,400,000
Weighted average amortization period		7 years
Analytical Wizards [Member]
Business Acquisition [Line Items]
Purchase price			99,400,000
Trade Names [Member]
Business Acquisition [Line Items]
Other assets	100,000				500,000
Trade Names [Member] | Populi Inc. [Member]
Business Acquisition [Line Items]
Other assets	100,000
Weighted average amortization period		1 year
Customer Relationships [Member]
Business Acquisition [Line Items]
Other assets	1,300,000		39,400,000
Customer Relationships [Member] | Populi Inc. [Member]
Business Acquisition [Line Items]
Other assets	1,300,000
Weighted average amortization period		20 years
Goodwill [Member]
Business Acquisition [Line Items]
Other assets	36,700,000		61,500,000
Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Potential payouts range, Low	0				0
Potential payouts range, High	$ 28,000,000				5,000,000
AW Acquisition [Member]
Business Acquisition [Line Items]
Fair value of the contingent consideration			$ 1,000,000
Weighted average amortization period			20 years
Transaction costs paid from proceeds							$ 1,300,000
Date of acquisition			Feb. 18, 2022
Business combination, Contingent consideration, Liability						$ 2,300,000
AW Acquisition [Member] | Software Development [Member]
Business Acquisition [Line Items]
Other assets					6,100,000
Weighted average amortization period			6 years
AW Acquisition [Member] | Trade Names [Member]
Business Acquisition [Line Items]
Weighted average amortization period			5 years
AW Acquisition [Member] | Trademarks [Member]
Business Acquisition [Line Items]
Other assets					500,000
Weighted average amortization period			5 years
AW Acquisition [Member] | Customer Relationships [Member]
Business Acquisition [Line Items]
Other assets					$ 39,400,000
Weighted average amortization period			20 years
Call Option [Member]
Business Acquisition [Line Items]
Stock issued during period value stock options exercised				$ 65,000,000
Option indexed to issuers equity settlement alternatives cash at fair value				$ 7,300,000
Series B Preferred Stock [Member]
Business Acquisition [Line Items]
Preferred stock convertible conversion ratio				0.35
Option indexed to issuers equity settlement alternatives cash at fair value				$ 32,700,000
Series B Preferred Stock [Member] | Purchase Option Member
Business Acquisition [Line Items]
Option indexed to issuers equity settlement alternatives cash at fair value				$ 40,000,000

Acquisition - Summary of Transa

Acquisition - Summary of Transaction Transferred (Details) - USD ($) $ in Thousands			9 Months Ended	12 Months Ended
	Jul. 21, 2023	Feb. 18, 2022	Sep. 30, 2023	Dec. 31, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Initial cash investment in December 2021		$ 40,000
Cash consideration paid at closing	$ 46,400	58,600
Working capital adjustments	200	200
Contingent consideration	28,000	$ 5,000
Populi Inc. [Member]
Business Acquisition [Line Items]
Cash consideration paid at closing	4,800		$ 46,446
Working capital adjustments			(164)
Contingent consideration			7,800
Purchase price	$ 54,100		$ 54,082
AW acquisition
Business Acquisition [Line Items]
Initial cash investment in December 2021					$ 40,000
Cash consideration paid at closing				$ 58,645
Working capital adjustments				(202)
Contingent consideration				1,000
Purchase price				$ 99,443

Acquisitions - Summary of Alloc

Acquisitions - Summary of Allocation of Purchase Price to the Fair Value of Assets Acquired (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Mar. 31, 2023
Populi Inc. [Member]
Cash	$ 1,423
Accounts receivable	2,662
Prepaid expenses and other current assets	153
Property and equipment	42
Intangible assets	22,830
Accounts payable and accrued expenses	(3,316)
Deferred revenue	(4,010)
Other liabilities	(2,354)
Total assets acquired and liabilities assumed	17,430
Goodwill	36,652
Purchase price	$ 54,082
AW acquisition
Cash		$ 2,146
Accounts receivable		3,525
Prepaid expenses and other current assets		847
Property and equipment		134
Intangible assets		46,000
Right-of-use asset, operating leases		832
Other assets		703
Accounts payable and accrued expenses		(1,028)
Deferred revenue		(3,365)
Right-of-use liability, operating leases		(832)
Deferred taxes		(10,278)
Other liabilities		(900)
Total assets acquired and liabilities assumed		37,784
Goodwill		61,659
Purchase price		99,443
AW acquisition | Preliminary, as originally reported
Cash		2,146
Accounts receivable		3,575
Prepaid expenses and other current assets		506
Property and equipment		134
Intangible assets		46,000
Right-of-use asset, operating leases		832
Other assets		0
Accounts payable and accrued expenses		(485)
Deferred revenue		(3,691)
Right-of-use liability, operating leases		(832)
Deferred taxes		(10,345)
Other liabilities		(267)
Total assets acquired and liabilities assumed		37,573
Goodwill		62,072
Purchase price		99,645
AW acquisition | Measurement period adjustments
Cash		0
Accounts receivable		(50)
Prepaid expenses and other current assets		341
Property and equipment		0
Intangible assets		0
Right-of-use asset, operating leases		0
Other assets		703
Accounts payable and accrued expenses		(543)
Deferred revenue		326
Right-of-use liability, operating leases		0
Deferred taxes		67
Other liabilities		(633)
Total assets acquired and liabilities assumed		211
Goodwill		(413)
Purchase price		$ (202)

Acquisitions - Schedule of Busi

Acquisitions - Schedule of Business Acquisition, Pro Forma Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Populi, Inc. [Member]
Business Acquisition [Line Items]
Revenue	$ 189,697	$ 166,204
Net loss	$ (280,870)	(36,423)
AW Acquisition [Member]
Business Acquisition [Line Items]
Revenue		163,531
Net loss		$ (29,566)

Revenue - Schedule of Disaggreg

Revenue - Schedule of Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation Of Revenue [Line Items]
Revenue	$ 65,325	$ 57,382	$ 185,483	$ 162,054
Subscription Services [Member]
Disaggregation Of Revenue [Line Items]
Revenue	62,568	56,156	180,358	159,136
Professional Services [Member]
Disaggregation Of Revenue [Line Items]
Revenue	$ 2,757	$ 1,226	$ 5,125	$ 2,918

Revenue - Summary of Receivable

Revenue - Summary of Receivables, Deferred Contract Costs and Contract Liabilities from Contract with Customers (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Accounts receivable, net	$ 41,308	$ 58,799
Deferred contract costs, current portion	12,396	10,387
Deferred contract costs, long-term	16,132	14,596
Deferred revenues	$ 89,781	$ 99,928

Revenue - Summary of Deferred C

Revenue - Summary of Deferred Contract Costs (Details) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Additional amounts deferred	$ 175,336		$ 238,558
Current	16,132		14,596
Total deferred contract costs (deferred commissions)	(13,020)	$ (10,070)
Deferred Contract Costs [Member]
Disaggregation of Revenue [Line Items]
Balance at beginning of period	24,983	$ 18,547	18,547
Costs amortized	(9,475)		(8,816)
Additional amounts deferred	13,020		15,252
Balance at end of period	28,528		24,983
Current	12,396		10,387
Non-current	16,132		14,596
Total deferred contract costs (deferred commissions)	$ 28,528		$ 24,983

Revenue - Summary of Deferred R

Revenue - Summary of Deferred Revenue Balances (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Balance at beginning of period	$ 99,928	$ 84,023
Revenue recognized	(185,483)	(222,653)
Additional amounts deferred	175,336	238,558
Balance at end of period	$ 89,781	$ 99,928

Revenue - Summary of Remaining

Revenue - Summary of Remaining Performance Obligation (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Current	$ 170,782	$ 183,527
Noncurrent	82,462	93,464
Total	$ 253,244	$ 276,991

Short-term Investments - Schedu

Short-term Investments - Schedule of short-term Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	$ 229,846	$ 185,164
Gross unrealized gains	4	53
Gross unrealized losses	(285)	(278)
Fair Value	229,565	184,939
U.S. Treasuries [Member]
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	96,668	59,849
Gross unrealized gains	0	3
Gross unrealized losses	(197)	(129)
Fair Value	96,471	59,723
Agency Bonds [Member]
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	1,107	6,450
Gross unrealized gains	0	4
Gross unrealized losses	0	(2)
Fair Value	1,107	6,452
Corporate Bonds [Member]
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	2,280
Gross unrealized gains	0
Gross unrealized losses	0
Fair Value	2,280
Commercial Paper [Member]
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	104,719	95,831
Gross unrealized gains	1	29
Gross unrealized losses	(74)	(123)
Fair Value	104,646	95,737
Certificates of Deposit [Member]
Debt Securities, Available-for-Sale [Line Items]
Amortized Cost	25,072	23,034
Gross unrealized gains	3	17
Gross unrealized losses	(14)	(24)
Fair Value	$ 25,061	$ 23,027

Accounts Receivable - Schedule

Accounts Receivable - Schedule of Accounts Receivable (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Receivables [Abstract]
Accounts receivable	$ 42,037	$ 59,780
Unbilled receivable	959	881
Accounts Receivable, before Allowance for Credit Loss, Current	42,996	60,661
Less: allowance for doubtful accounts	(1,688)	(1,862)
Accounts receivable, net	$ 41,308	$ 58,799

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 10,706	$ 9,262
Less: accumulated depreciation and amortization	(6,078)	(4,798)
Property and equipment, net	4,628	4,464
Computers and Software [Member]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Gross	7,003	5,924
Furniture and Equipment [Member]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Gross	1,420	1,204
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 2,283	$ 2,134

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Property Plant And Equipment [Line Items]
Depreciation and amortization	$ 9,795	$ 10,037	$ 29,073	$ 30,105
Property Plant And Equipment [Member]
Property Plant And Equipment [Line Items]
Depreciation and amortization	$ 400	$ 500	$ 1,300	$ 1,700

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Schedule of Intangible Assets and Goodwill (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 575,259	$ 552,524
Accumulated Amortization	(239,232)	(201,802)
Net Carrying Amount	336,027	350,722
Goodwill [Member]
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,073,986	1,324,733
Accumulated Amortization	0	0
Net Carrying Amount	1,073,986	1,324,733
Goodwill And Intangible Assets [Member]
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,649,245	1,877,257
Accumulated Amortization	(239,232)	(201,802)
Net Carrying Amount	1,410,013	1,675,455
Customer Relationships [Member]
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	410,710	409,430
Accumulated Amortization	(154,789)	(128,745)
Net Carrying Amount	255,921	280,685
Developed Technologies [Member]
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	78,324	56,965
Accumulated Amortization	(31,627)	(25,514)
Net Carrying Amount	46,697	31,451
Trade Names [Member]
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	36,021	35,914
Accumulated Amortization	(8,775)	(7,150)
Net Carrying Amount	27,246	28,764
Database [Member]
Finite Lived Intangible Assets [Line Items]
Gross Carrying Amount	50,204	50,215
Accumulated Amortization	(44,041)	(40,393)
Net Carrying Amount	$ 6,163	$ 9,822

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Additional Information (Details) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) Segment	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Finite Lived Intangible Assets [Line Items]
Amortization of intangible assets			$ 37,358	$ 42,497
Amortization	$ 3,232	$ 3,155	$ 9,676	14,113
Number of Reporting Units | Segment			1
Goodwill impairment	287,400	0	$ 287,400	0	$ 0
Finite Lived Intangible Assets [Member]
Finite Lived Intangible Assets [Line Items]
Amortization of intangible assets	12,600	12,700	37,400	42,500
Amortization	$ 3,200	$ 3,200	$ 9,700	$ 14,100

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Schedule of Future Amortization Expense (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
2023, excluding the nine months ended September 30, 2023	$ 12,479
2024	48,455
2025	45,945
2026	39,305
2027	33,357
Thereafter	156,486
Net Carrying Amount	$ 336,027	$ 350,722

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Schedule of Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill - beginning of period			$ 1,324,733	$ 1,263,075	$ 1,263,075
Goodwill acquired during period			36,653		61,658
Goodwill impairment loss	$ (287,400)	$ 0	(287,400)	0	0
Goodwill - end of period	$ 1,073,986	$ 1,324,590	$ 1,073,986	$ 1,324,590	$ 1,324,733

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses And Other Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Accounts Payable and Accrued Liabilities, Current [Abstract]
Payroll and payroll-related	$ 10,503	$ 11,961
Tax receivable agreement, current portion	6,673	0
Contingent consideration, current	2,250	0
Sales, franchise and other taxes	11,352	11,738
Other	5,208	3,156
Accrued expenses and other current liabilities	$ 35,986	$ 26,855

Accrued Expenses and Other Cu_4

Accrued Expenses and Other Current Liabilities - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023	Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring and related charges	$ 2.1	$ 4.6
Restructuring and related cost, remaining	0.5	0.5
Sales tax accrual payable including assumed maximum penalties and interest	$ 9.2	$ 9.2	$ 8.1

Long-Term Debt - Schedule of Lo

Long-Term Debt - Schedule of Long-term Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Less: current portion of long-term debt	$ 13,750	$ 8,594
Long-term debt	245,866	255,765
2021 Term Loan [Member]
Debt Instrument [Line Items]
Principal	261,250	266,406
Unamortized debt issuance costs / financing costs	(1,634)	(2,047)
Total debt, net	$ 259,616	$ 264,359

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Frequency of payment		The 2021 Term Loan is subject to annual amortization of principal, payable in equal quarterly installments on the last day of each fiscal quarter, commencing on December 31, 2021 (the “Initial Amortization Date”), equal to approximately 2.5% per annum of the principal amount of the term loans in the first year and second year after the Initial Amortization Date and approximately 5.0% per annum of the principal amount of the term loans in the third year, fourth year, and fifth year after the Initial Amortization Date.
Financing costs		$ 3,500
2021 Term Loan [Member]
Debt Instrument [Line Items]
Repayment of debt		5,200
Outstanding principal balance		261,250	$ 266,406
Line of credit	$ 275,000
Balloon payment		220,000
Financing costs		2,800
Unamortized debt issuance costs / financing costs		$ (1,634)	$ (2,047)
2021 Revolving Line of Credit [Member]
Debt Instrument [Line Items]
Maturity date	Sep. 17, 2026
Line of credit	$ 75,000
Interest rate		7.17%
Financing costs		$ 800
Unamortized debt issuance costs / financing costs		$ 400
2021 Revolving Line of Credit [Member] | Minimum [Member]
Debt Instrument [Line Items]
Unused commitment fee percentage		0.25%
2021 Revolving Line of Credit [Member] | Maximum [Member]
Debt Instrument [Line Items]
Unused commitment fee percentage		0.30%

Derivative Instruments and He_3

Derivative Instruments and Hedging Activities - Additional Information (Details)	9 Months Ended
	Sep. 30, 2023 USD ($) Segment	Dec. 31, 2022 USD ($)	Mar. 31, 2022 Segment
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Net pre-tax gains	$ 0	$ 0
Interest Rate Swaps [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, Number of Instruments Held | Segment	2		2
Notional amount	$ 65,300,000
Maturity date	Mar. 31, 2025
Net pre-tax gains	$ 4,300,000
Interest Rate Swaps [Member] | Goldman Sachs Bank USA [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Fixed interest rates	1.9065%
Interest Rate Swaps [Member] | Bank of America N.A [Member]
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Fixed interest rates	1.909%

Derivative Instruments and He_4

Derivative Instruments and Hedging Activities - Summary of Fair Values of the Interest Rate Swap (Details) - Interest Rate Swap [Member] - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Short-term derivative asset	$ 4,266	$ 3,716
Derivative Asset, Current, Statement of Financial Position [Extensible Enumeration]	Prepaid Expense and Other Assets, Current	Prepaid Expense and Other Assets, Current
Long-term derivative asset	$ 1,600	$ 2,834
Derivative Asset, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other Assets, Noncurrent	Other Assets, Noncurrent

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Business combination, Contingent consideration, Liability	$ 7,800		$ 7,800
Business Combination, Contingent Consideration, Liability, Current	2,300		2,300
Goodwill impairment charge	$ 287,400	$ 0	$ 287,400	$ 0	$ 0

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Reconciliation of Earnout Liabilities Measured at Fair Value on a Recurring Basis Unobservable Inputs (Details) - Fair Value, Inputs, Level 3 - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Balance at beginning of period	$ 2,250	$ 7,500
Additions	7,800	1,000
Net change in fair value and other adjustments	0	1,250
Payments	0	(7,500)
Balance at end of period	$ 10,050	$ 2,250

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Fair Value of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current portion of contingent consideration	$ 2,300
Contingent consideration	7,800	$ (1,000)
Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current portion of contingent consideration	2,250
Long-term portion of contingent consideration	7,800
Recurring [Member] | U.S. Treasuries [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	96,471		$ 59,723
Recurring [Member] | Agency Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	1,107		6,452
Recurring [Member] | Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	2,280
Recurring [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	104,646		95,737
Recurring [Member] | Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	25,061		23,027
Recurring [Member] | Interest Rate Swap [Member] | Prepaid Expenses and Other Current Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	4,266		3,716
Recurring [Member] | Interest Rate Swap [Member] | Other Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	1,600		2,834
Recurring [Member] | Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration			2,250
Recurring [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	46,946		39,523
Recurring [Member] | Commercial Paper Maturities Less Than 90 Days [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	6,222		2,276
Recurring [Member] | Certificates of Deposit Maturities Less Than 90 Days [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets			1,549
Recurring [Member] | Agency Bonds Maturities Less Than 90 Days [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets			768
Level 1 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current portion of contingent consideration	0
Long-term portion of contingent consideration	0
Level 1 [Member] | Recurring [Member] | U.S. Treasuries [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0		0
Level 1 [Member] | Recurring [Member] | Agency Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0		0
Level 1 [Member] | Recurring [Member] | Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0
Level 1 [Member] | Recurring [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0		0
Level 1 [Member] | Recurring [Member] | Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0		0
Level 1 [Member] | Recurring [Member] | Interest Rate Swap [Member] | Prepaid Expenses and Other Current Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0		0
Level 1 [Member] | Recurring [Member] | Interest Rate Swap [Member] | Other Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0		0
Level 1 [Member] | Recurring [Member] | Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration			0
Level 1 [Member] | Recurring [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	46,946		39,523
Level 1 [Member] | Recurring [Member] | Commercial Paper Maturities Less Than 90 Days [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0		0
Level 1 [Member] | Recurring [Member] | Certificates of Deposit Maturities Less Than 90 Days [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets			0
Level 1 [Member] | Recurring [Member] | Agency Bonds Maturities Less Than 90 Days [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets			0
Level 2 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current portion of contingent consideration	0
Long-term portion of contingent consideration	0
Level 2 [Member] | Recurring [Member] | U.S. Treasuries [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	96,471		59,723
Level 2 [Member] | Recurring [Member] | Agency Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	1,107		6,452
Level 2 [Member] | Recurring [Member] | Corporate Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	2,280
Level 2 [Member] | Recurring [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	104,646		95,737
Level 2 [Member] | Recurring [Member] | Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	25,061		23,027
Level 2 [Member] | Recurring [Member] | Interest Rate Swap [Member] | Prepaid Expenses and Other Current Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	4,266		3,716
Level 2 [Member] | Recurring [Member] | Interest Rate Swap [Member] | Other Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	1,600		2,834
Level 2 [Member] | Recurring [Member] | Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration			0
Level 2 [Member] | Recurring [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0		0
Level 2 [Member] | Recurring [Member] | Commercial Paper Maturities Less Than 90 Days [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	6,222		2,276
Level 2 [Member] | Recurring [Member] | Certificates of Deposit Maturities Less Than 90 Days [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets			1,549
Level 2 [Member] | Recurring [Member] | Agency Bonds Maturities Less Than 90 Days [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets			768
Level 3 [Member] | Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Current portion of contingent consideration	2,250
Long-term portion of contingent consideration	7,800
Level 3 [Member] | Recurring [Member] | U.S. Treasuries [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0		0
Level 3 [Member] | Recurring [Member] | Agency Bonds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0		0
Level 3 [Member] | Recurring [Member] | Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0		0
Level 3 [Member] | Recurring [Member] | Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0		0
Level 3 [Member] | Recurring [Member] | Interest Rate Swap [Member] | Prepaid Expenses and Other Current Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0		0
Level 3 [Member] | Recurring [Member] | Interest Rate Swap [Member] | Other Assets [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0		0
Level 3 [Member] | Recurring [Member] | Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration			2,250
Level 3 [Member] | Recurring [Member] | Money Market Funds [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	0		0
Level 3 [Member] | Recurring [Member] | Commercial Paper Maturities Less Than 90 Days [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets	$ 0		0
Level 3 [Member] | Recurring [Member] | Certificates of Deposit Maturities Less Than 90 Days [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets			0
Level 3 [Member] | Recurring [Member] | Agency Bonds Maturities Less Than 90 Days [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets			$ 0

Stockholders' Equity and Member

Stockholders' Equity and Members' Equity - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022
Class Of Stock [Line Items]
Equity-based compensation	$ 11,994	$ 12,363	$ 11,128	$ 9,133	$ 9,005	$ 6,872

Noncontrolling Interest - Addit

Noncontrolling Interest - Additional Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Noncontrolling Interest [Line Items]
Tax withholding obligation	$ 3,397	$ 2,745
Common Class A
Noncontrolling Interest [Line Items]
Common stock, shares outstanding	116,281,962		105,138,273
Definitive OpCo [Member]
Noncontrolling Interest [Line Items]
Ownership interest (as a percent)	74.80%		68.20%
Noncontrolling interest	25.20%		31.80%
Definitive OpCo [Member] | Common Class A
Noncontrolling Interest [Line Items]
Tax withholding obligation	$ 308,295
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	904,919
Issuance of common stock shares	596,624
Continuing Pre-IPO LLC Members [Member] | Common Class A
Noncontrolling Interest [Line Items]
Common stock, shares outstanding	10,547,065

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income - Summary of Changes in Accumulated Balances in Other Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Unrealized Gain (Loss) on Cash Flow Hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	$ 4,158		$ 2,150	$ 4,307	$ 0
Other comprehensive (loss) income before reclassifications	505		2,288	1,710	4,162
Amounts reclassified from AOCI	(832)		47	(2,186)	229
Ending Balance	3,831	$ 4,158	4,391	3,831	4,391
Unrealized (Loss) Gain on Investments
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	(326)		(290)	(135)	0
Other comprehensive (loss) income before reclassifications	(148)		(31)	(43)	(259)
Amounts reclassified from AOCI	0		0	0	0
Ending Balance	(178)	(326)	(259)	(178)	(259)
Foreign Currency Translation Adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	(580)		187	(504)	62
Other comprehensive (loss) income before reclassifications	(22)		(34)	(98)	(283)
Amounts reclassified from AOCI	0		0	0	0
Ending Balance	(602)	(580)	(221)	(602)	(221)
AOCI Attributable to Parent [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning Balance	3,051	3,252	1,673	3,668	62
Other comprehensive (loss) income before reclassifications		631	2,285	1,569	3,620
Amounts reclassified from AOCI		(832)	47	(2,186)	229
Ending Balance	$ 3,051	$ 3,051	$ 3,911	$ 3,051	$ 3,911

Equity-Based Compensation Expen

Equity-Based Compensation Expense - Summary of Equity Based Compensation Expense Recognized (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 11,994	$ 9,133	$ 35,485	$ 25,010
Cost of Revenue
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	276	236	830	698
Sales and Marketing
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	2,728	2,260	8,297	11,062
Product Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	3,236	2,171	9,566	5,301
General And Administrative Expense
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 5,754	$ 4,466	$ 16,792	$ 7,949

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Tax Credit Carryforward [Table]
Unrecognized tax benefits	$ 0		$ 0		$ 0
Effective tax rate	6.60%	0.20%	6.70%	2.10%
Deferred tax liabilities	$ 65,400,000		$ 65,400,000		75,600,000
Tax receivable agreement liability			$ 145,400,000		$ 155,100,000
Tax receivable agreement realized tax benefits payable to related parties percent			85%
Tax Receivable Agreement Benefit percentage			15%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			21%
TRA Remeasurement Gain (Loss)	$ 29,700,000	$ 5,300,000	$ 25,000,000	$ 8,600,000

Loss Per Share - Schedule of Ne

Loss Per Share - Schedule of Net Loss Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Net loss	$ (248,688)	$ (11,605)	$ (15,972)	$ (6,885)	$ (10,142)	$ (13,039)	$ (276,265)	$ (30,066)
Less: Net loss attributable to noncontrolling interests	(77,162)			(3,865)			(84,110)	(12,979)
Net loss attributable to Definitive Healthcare Corp.	(171,526)			(3,020)			(192,155)	(17,087)
Basic net loss per share attributable to common stockholders [Abstract]
Allocation of net loss attributable to Definitive Healthcare Corp.	$ (171,526)			$ (3,020)			$ (192,155)	$ (17,087)
Weighted average number of shares of Class A outstanding	114,527,514			102,904,565			111,533,166	99,776,742
Net loss per share, basic	$ (1.5)			$ (0.03)			$ (1.72)	$ (0.17)
Net loss per share, diluted	$ (1.5)			$ (0.03)			$ (1.72)	$ (0.17)
Common Class A [Member]
Net loss	$ (248,688)			$ (6,885)			$ (276,265)	$ (30,066)
Less: Net loss attributable to noncontrolling interests	(77,162)			(3,865)			(84,110)	(12,979)
Net loss attributable to Definitive Healthcare Corp.	(171,526)			(3,020)			(192,155)	(17,087)
Basic net loss per share attributable to common stockholders [Abstract]
Allocation of net loss attributable to Definitive Healthcare Corp.	$ (171,526)			$ (3,020)			$ (192,155)	$ (17,087)
Weighted average number of shares of Class A outstanding	114,527,514			102,904,565			111,533,166	99,776,742
Net loss per share, basic	$ (1.5)			$ (0.03)			$ (1.72)	$ (0.17)
Net loss per share, diluted	$ (1.5)			$ (0.03)			$ (1.72)	$ (0.17)

Loss Per Share - Schedule of Di

Loss Per Share - Schedule of Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Vested and Unvested Units [Member]
Antidilutive securities excluded from computation of earnings per share, amount	39,781,946	50,566,898
Restricted Stock Unit [Member]
Antidilutive securities excluded from computation of earnings per share, amount	6,847,050	3,411,944

Related parties - Additional In

Related parties - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Related Party Transaction [Line Items]
Revenue	$ 65,325	$ 57,382	$ 185,483	$ 162,054
Accounts receivable, net	41,308		41,308		$ 58,799
Related Party [Member]
Related Party Transaction [Line Items]
Revenue	$ 300	$ 200	$ 1,100	$ 700
Accounts receivable, net					$ 800